Yarrow Bioscience, Inc 8-K/A, filed May 7, 2020
Yarrow Bioscience, Inc. (YARW)
About this 8-K/A
Yarrow Bioscience, Inc filed this 8-K/A on May 7, 2020, reporting on events of March 9, 2020.
Items reported
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) May 7, 2020 (March 9, 2020)
Menlo Therapeutics Inc.
(Exact name of registrant as specified in its charter)
| Delaware (State or other jurisdiction of incorporation) |
001-38356 (Commission File Number) |
45-3757789 (I. R. S. Employer Identification No.) |
520 U.S. Highway 22, Suite 204
Bridgewater, New
Jersey 08807
(Address of principal executive offices, including ZIP code)
(800) 755-7936
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CI-’R 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange | ||
| Common Stock, par value $0.0001 | MNLO | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
Explanatory Note
On March 9, 2020, pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the “Merger Agreement”), by and among Menlo Therapeutics Inc. (“Menlo” or the “Company”), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel (“Foamix”), and Giants Merger Subsidiary, Ltd., a direct, wholly owned subsidiary of the Company (“Merger Sub”), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of the Company (the “Merger”).
This Current Report on Form 8-K/A amends and supplements Item 9.01 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 10, 2020, related to the completion of the Merger (the “Original Form 8-K”). The purpose of this amendment is to provide certain historical financial statements for Foamix and certain pro forma financial information in connection with the Merger.
Except as set forth herein, no modifications have been made to the information contained in the Original Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(a) Financial Statements of Business Acquired
The historical audited consolidated balance sheets of Foamix as of December 31, 2019 and 2018 and the related consolidated statements of operations, comprehensive loss, changes in shareholders’ equity and cash flows for each of the three years in the period ended December 31, 2019 are included as Exhibit 99.1 hereto and incorporated by reference in this Item 9.01(a).
(b) Pro Forma Financial Information
The Company’s unaudited pro forma combined financial information and explanatory notes for the year ended December 31, 2019 are included as Exhibit 99.2 hereto and incorporated by reference in this Item 9.01(b).
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Menlo Therapeutics Inc. | |
| /s/ Mutya Harsch | |
| By: Mutya Harsch | |
| Chief Legal Officer and General Counsel |
Date: May 7, 2020
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-229482) and Form S-8 (Nos. 333-222758, 333-229975 and 333-237041) of Menlo Therapeutics Inc. of our report dated March 12, 2020 relating to the financial statements of Foamix Pharmaceuticals Ltd., which appears in this Current Report on Form 8-K/A.
| Tel-Aviv, Israel | /s/ Kesselman & Kesselman |
| May 7, 2020 | Certified Public Accountants (Isr.) |
| A member firm of PricewaterhouseCoopers International Limited |
Kesselman & Kesselman, Trade Tower, 25 Hamered Street, Tel-Aviv 6812508, Israel,
P.O Box 50005 Tel-Aviv 6150001 Telephone: +972 -3- 7954555, Fax:+972 -3- 7954556, www.pwc.com/il
Exhibit 99.1
FOAMIX PHARMACEUTICALS LTD.
CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2019
F- 1 -
FOAMIX PHARMACEUTICALS LTD.
CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2019
INDEX
| Page | |
| Report of Independent Registered Public Accounting Firm | F-2 |
| Consolidated Balance Sheets | F-3 |
| Consolidated Statements of Operations | F-5 |
| Consolidated Statements of Comprehensive Loss | F-6 |
| Statements of Changes in Shareholders’ Equity | F-7 |
| Consolidated Statements of Cash Flows | F-8 |
| Notes to Consolidated Financial Statements | F-10 |
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the shareholders and the board of directors of
FOAMIX PHARMACEUTICALS LTD.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Foamix Pharmaceuticals Ltd. and its subsidiary (the “Company”) as of December 31, 2019 and 2018, and the related consolidated statements of operations, comprehensive loss, changes in shareholders' equity and cash flows for each of the three years in the period ended December 31, 2019, including the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2019 in conformity with accounting principles generally accepted in the United States of America.
Change in Accounting Principle
As discussed in Note 2(y) to the consolidated financial statements, the Company changed the manner in which it accounts for leases in 2019.
Basis for Opinion
These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.
| Tel-Aviv, Israel | /s/ Kesselman & Kesselman |
| March 12, 2020 | Certified Public Accountants (Isr.) |
| A member firm of PricewaterhouseCoopers International Limited |
We have served as the Company's auditor since 2006.
Kesselman & Kesselman, Trade Tower, 25 Hamered Street, Tel-Aviv 6812508, Israel,
P.O Box 50005 Tel-Aviv 6150001 Telephone: +972 -3- 7954555, Fax:+972 -3- 7954556, www.pwc.com/il
FOAMIX PHARMACEUTICALS LTD.
CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands)
| December 31 | ||||||||
| 2019 | 2018 | |||||||
| A s s e t s | ||||||||
| CURRENT ASSETS: | ||||||||
| Cash and cash equivalents | $ | 43,759 | $ | 27,868 | ||||
| Restricted cash | 825 | 250 | ||||||
| Short term bank deposits | 12,102 | 24,047 | ||||||
| Investment in marketable securities (Note 4) | 16,246 | 46,669 | ||||||
| Restricted investment in marketable securities (Note 4) | 434 | 268 | ||||||
| Trade receivable | 135 | 1,066 | ||||||
| Other (Note 13a) | 1,557 | 999 | ||||||
| Inventory (Note 5) | 1,356 | - | ||||||
| TOTAL CURRENT ASSETS | 76,414 | 101,167 | ||||||
| NON-CURRENT ASSETS: | ||||||||
| Investment in marketable securities (Note 4) | - | 150 | ||||||
| Restricted investment in marketable securities (Note 4) | - | 133 | ||||||
| Property and equipment, net (Note 6) | 2,885 | 2,235 | ||||||
| Operating lease right of use assets (Note 7) | 1,694 | - | ||||||
| Other | 166 | 46 | ||||||
| TOTAL NON-CURRENT ASSETS | 4,745 | 2,564 | ||||||
| TOTAL ASSETS | $ | 81,159 | $ | 103,731 | ||||
The accompanying notes are an integral part of these consolidated financial statements.
F-3
FOAMIX PHARMACEUTICALS LTD.
CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands)
| December 31 | ||||||||
| 2019 | 2018 | |||||||
| Liabilities and shareholders’ equity | ||||||||
| CURRENT LIABILITIES: | ||||||||
| Trade payables | $ | 19,352 | $ | 6,327 | ||||
| Accrued expenses | 3,381 | 351 | ||||||
| Employee related obligations | 5,231 | 3,498 | ||||||
| Operating lease liabilities (Note 7) | 1,092 | - | ||||||
| Other | 270 | 292 | ||||||
| TOTAL CURRENT LIABILITIES | 29,326 | 10,468 | ||||||
| LONG-TERM LIABILITIES: | ||||||||
| Liability for employee severance benefits (Note 8) | 424 | 367 | ||||||
| Operating lease liabilities (Note 7) | 653 | - | ||||||
| Long-term debt (Note 10) | 32,725 | - | ||||||
| Other liabilities | 456 | 714 | ||||||
| TOTAL LONG-TERM LIABILITIES | 34,258 | 1,081 | ||||||
| TOTAL LIABILITIES | 63,584 | 11,549 | ||||||
| COMMITMENTS AND CONTINGENCIES (Note 9) | ||||||||
| SHAREHOLDERS' EQUITY: | ||||||||
| Ordinary Shares, NIS 0.16 par value - authorized: 135,000,000 and 90,000,000 Ordinary Shares as of December 31, 2019 and December 31, 2018; issued and outstanding: 61,580,544 and 54,351,140 Ordinary Shares as of December 31, 2019 and December 31, 2018, respectively | 2,659 | 2,331 | ||||||
| Additional paid-in capital | 325,498 | 305,303 | ||||||
| Accumulated deficit | (310,587 | ) | (215,409 | ) | ||||
| Accumulated other comprehensive income (loss) | 5 | (43 | ) | |||||
| TOTAL SHAREHOLDERS' EQUITY | 17,575 | 92,182 | ||||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ | 81,159 | $ | 103,731 | ||||
The accompanying notes are an integral part of these consolidated financial statements.
F-4
FOAMIX PHARMACEUTICALS LTD.
CONSOLIDATED STATEMENTS OF OPERATIONS
(U.S. dollars in thousands, except per share data)
| Year ended December 31 | ||||||||||||
| 2019 | 2018 | 2017 | ||||||||||
| REVENUES (Note 13b) | $ | 443 | $ | 3,595 | $ | 3,669 | ||||||
| COST OF REVENUES | - | - | 13 | |||||||||
| GROSS PROFIT | 443 | 3,595 | 3,656 | |||||||||
| OPERATING EXPENSES: | ||||||||||||
| Research and development | 51,202 | 64,474 | 57,779 | |||||||||
| Selling, general and administrative | 45,114 | 14,013 | 11,491 | |||||||||
| TOTAL OPERATING EXPENSES | 96,316 | 78,487 | 69,270 | |||||||||
| OPERATING LOSS | 95,873 | 74,892 | 65,614 | |||||||||
| FINANCE INCOME (Note 13c) | (1,672 | ) | (985 | ) | (1,134 | ) | ||||||
| FINANCE EXPENSES (Note 13c) | 1,153 | 44 | 71 | |||||||||
| LOSS BEFORE INCOME TAX | 95,354 | 73,951 | 64,551 | |||||||||
| INCOME TAX (Note 12) | (176 | ) | 212 | 1,164 | ||||||||
| NET LOSS FOR THE YEAR | $ | 95,178 | $ | 74,163 | $ | 65,715 | ||||||
| LOSS PER SHARE BASIC AND DILUTED | $ | 1.66 | $ | 1.70 | $ | 1.76 | ||||||
| WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE IN THOUSANDS | 57,292 | 43,660 | 37,376 | |||||||||
The accompanying notes are an integral part of these consolidated financial statements.
F-5
FOAMIX PHARMACEUTICALS LTD.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(U.S. dollars in thousands)
| Year ended December 31 | ||||||||||||
| 2019 | 2018 | 2017 | ||||||||||
| NET LOSS | $ | 95,178 | $ | 74,163 | $ | 65,715 | ||||||
| OTHER COMPREHENSIVE INCOME: | ||||||||||||
| Net unrealized losses (gains) from marketable securities | (47 | ) | (59 | ) | 5 | |||||||
| Gains (losses) on marketable securities reclassified into net loss | 2 | (5 | ) | - | ||||||||
| Net unrealized losses (gains) on derivative financial instruments | (3 | ) | 74 | (146 | ) | |||||||
| Gains (losses) on derivative financial instruments reclassified into net loss | - | (60 | ) | 137 | ||||||||
| TOTAL OTHER COMPREHENSIVE INCOME | (48 | ) | (50 | ) | (4 | ) | ||||||
| TOTAL COMPREHENSIVE LOSS | $ | 95,130 | $ | 74,113 | $ | 65,711 | ||||||
The accompanying notes are an integral part of these consolidated financial statements
F-6
FOAMIX PHARMACEUTICALS LTD.
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
(U.S. dollars in thousands, except share data)
| Ordinary shares | Additional paid-in capital | Accumulated deficit | Accumulated other comprehensive income (loss) | Total | ||||||||||||||||||||
| Number of shares | Amounts | Amounts | ||||||||||||||||||||||
| BALANCE AT JANUARY 1, 2017 | 37,167,791 | $ | 1,561 | $ | 204,052 | $ | (75,566 | ) | $ | (62 | ) | $ | 129,985 | |||||||||||
| CHANGES DURING 2017: | ||||||||||||||||||||||||
| Comprehensive income (loss) | - | - | - | (65,715 | ) | 4 | (65,711 | ) | ||||||||||||||||
| Exercise of warrants (Note 11b) | 191,793 | 8 | (8 | ) | - | - | - | |||||||||||||||||
| Exercise of options and restricted share units (Note 11e) | 138,544 | 7 | 154 | - | - | 161 | ||||||||||||||||||
| Share-based compensation (Note 11e) | - | - | 4,166 | - | - | 4,166 | ||||||||||||||||||
| BALANCE AT DECEMBER 31, 2017, as previously reported | 37,498,128 | $ | 1,576 | $ | 208,364 | $ | (141,281 | ) | $ | (58 | ) | $ | 68,601 | |||||||||||
| Impact of initial adoption of new accounting standards (Note 4) | - | - | - | 35 | (35 | ) | - | |||||||||||||||||
| CHANGES DURING 2018: | ||||||||||||||||||||||||
| Comprehensive income (loss) | - | - | - | (74,163 | ) | 50 | (74,113 | ) | ||||||||||||||||
| Issuance of Ordinary Shares through a public offering, net of $5.2 issuance costs (note 11c) | 13,420,500 | 599 | 74,757 | - | - | 75,356 | ||||||||||||||||||
| Issuance of Ordinary Shares through a securities purchase agreement, net of $39 issuance costs (note 11d) | 2,940,000 | 134 | 15,997 | - | - | 16,131 | ||||||||||||||||||
| Exercise of warrants (Note 11b) | 178,468 | 8 | 832 | - | - | 840 | ||||||||||||||||||
| Exercise of options and restricted share units (Note 11e) | 314,044 | 14 | 33 | - | - | 47 | ||||||||||||||||||
| Share-based compensation (Note 11e) | - | - | 5,320 | - | - | 5,320 | ||||||||||||||||||
| BALANCE AT DECEMBER 31, 2018 | 54,351,140 | $ | 2,331 | $ | 305,303 | $ | (215,409 | ) | $ | (43 | ) | $ | 92,182 | |||||||||||
| CHANGES DURING 2019: | ||||||||||||||||||||||||
| Comprehensive income (loss) | - | - | - | (95,178 | ) | 48 | (95,130 | ) | ||||||||||||||||
| Issuance of Ordinary Shares and warrants, net of $359 issuance costs (Notes 10 and 11) | 6,542,057 | 297 | 14,714 | - | - | 15,011 | ||||||||||||||||||
| Exercise of options, restricted share units and shares issued under employee share purchase plan (Note 11e) | 687,347 | 31 | 586 | - | - | 617 | ||||||||||||||||||
| Share-based compensation (Note 11e) | - | - | 4,895 | - | - | 4,895 | ||||||||||||||||||
| BALANCE AT DECEMBER 31, 2019 | 61,580,544 | $ | 2,659 | $ | 325,498 | $ | (310,587 | ) | $ | 5 | $ | 17,575 | ||||||||||||
The accompanying notes are an integral part of these consolidated financial statements
F-7
FOAMIX PHARMACEUTICALS LTD.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(U.S. dollars in thousands)
| Year ended December 31 | ||||||||||||
| 2019 | 2018 | 2017 | ||||||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||||||
| Net Loss | $ | (95,178 | ) | $ | (74,163 | ) | $ | (65,715 | ) | |||
| Adjustments required to reconcile net loss to net cash used in operating activities: | ||||||||||||
| Depreciation and amortization | 350 | 319 | 221 | |||||||||
| Loss from sale and disposal of fixed assets | 18 | 44 | 134 | |||||||||
| Changes in marketable securities and bank deposits, net | (357 | ) | 201 | 97 | ||||||||
| Changes in accrued liability for employee severance benefits, net of retirement fund profit | 57 | (70 | ) | 57 | ||||||||
| Share-based compensation | 4,895 | 5,320 | 4,166 | |||||||||
| Non-cash finance expenses (income), net | 140 | 43 | (47 | ) | ||||||||
| Changes in operating asset and liabilities: | ||||||||||||
| Decrease (increase) in trade and other receivables | 373 | (308 | ) | 1,915 | ||||||||
| Decrease (increase) in other non-current assets | (131 | ) | (14 | ) | 4 | |||||||
| Increase in accounts payable and accruals | 18,053 | 238 | 5,003 | |||||||||
| Increase in inventory | (1,356 | ) | - | - | ||||||||
| Increase (decrease) in other liabilities | (258 | ) | (274 | ) | 988 | |||||||
| Net cash used in operating activities | (73,394 | ) | (68,664 | ) | (53,177 | ) | ||||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||||||
| Purchase of fixed assets | (1,058 | ) | (567 | ) | (1,518 | ) | ||||||
| Proceeds from sale of fixed assets | 40 | 10 | 33 | |||||||||
| Investment in bank deposits | (26,013 | ) | (39,000 | ) | (17,000 | ) | ||||||
| Investment in marketable securities | (18,951 | ) | (38,652 | ) | (22,839 | ) | ||||||
| Proceeds from sale and maturity of marketable securities and bank deposits | 87,851 | 66,454 | 79,079 | |||||||||
| Net cash provided by (used in) investing activities | 41,869 | (11,755 | ) | 37,755 | ||||||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||||||
| Proceeds from exercise of warrants | - | 840 | - | |||||||||
| Proceeds from exercise of options and issuance of shares under the employee shares purchase plan | 365 | 47 | 161 | |||||||||
| Withholding tax from net exercise of restricted share units | (32 | ) | - | - | ||||||||
| Proceeds from issuance of Ordinary Shares, net of issuance costs | 13,714 | 16,131 | ||||||||||
| Proceeds from issuance of Ordinary Shares through a public offering, net of $5.2 issuance costs | - | 75,356 | - | |||||||||
| Proceeds from debt financing and issuance of warrants, net of $1,097 issuance costs | 33,903 | - | - | |||||||||
| Payments in respect of bank borrowings | - | - | (21 | ) | ||||||||
| Net cash provided by financing activities | 47,950 | 92,374 | 140 | |||||||||
INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | 16,425 | 11,955 | (15,282 | ) | ||||||||
EFFECT OF EXCHANGE RATE ON CASH, CASH EQUIVALENTS AND RESTRICTED CASH | 41 | (43 | ) | 48 | ||||||||
CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF THE YEAR | 28,118 | 16,206 | 31,440 | |||||||||
CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF THE YEAR | $ | 44,584 | $ | 28,118 | $ | 16,206 | ||||||
| Cash and cash equivalents | 43,759 | 27,868 | 15,956 | |||||||||
| Restricted cash | 825 | 250 | 250 | |||||||||
TOTAL CASH, CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH FLOWS | $ | 44,584 | $ | 28,118 | $ | 16,206 | ||||||
F-8
FOAMIX PHARMACEUTICALS LTD.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(U.S. dollars in thousands)
| Year ended December 31 | ||||||||||||
| 2019 | 2018 | 2017 | ||||||||||
SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS: | ||||||||||||
| Cashless exercise of warrants and restricted share units | 11 | 11 | 11 | |||||||||
| Issuance of shares under employee share purchase plan | 284 | - | - | |||||||||
| Property and equipment purchases included in accounts payable and accruals | - | - | 1 | |||||||||
| Additions to operating lease right of use assets and liabilities | 1,175 | - | - | |||||||||
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | ||||||||||||
| Cash paid for taxes | - | 587 | 478 | |||||||||
| Interest received | 1,359 | 1,173 | 1,209 | |||||||||
| Interest paid | 802 | - | *- | |||||||||
* Represents an amount less than $1.
The accompanying notes are an integral part of these consolidated financial statements.
F-9
FOAMIX PHARMACEUTICALS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S. dollars in thousands, except share and per share amounts)
NOTE 1 - NATURE OF OPERATIONS
Foamix Pharmaceuticals Ltd. (hereinafter “Foamix”) is an Israeli company incorporated in 2003.
Foamix’s shares were publicly traded on the Nasdaq Global Market under the symbol “FOMX” from its initial public offering in September 2014 until March 9, 2020.
Foamix is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies in dermatology. On October 18, 2019, the U.S. Food and Drug Administration (“FDA”) approved Foamix’s first drug product, AMZEEQ (minocycline) topical foam, 4%, formerly known as FMX101, a once-daily topical antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. AMZEEQ was launched and has been available for prescribing since January 13, 2020.
Foamix is also developing a product candidate, FMX103 (minocycline) topical foam, 1.5%, for the treatment of moderate-to-severe papulopustular rosacea in adults. Both AMZEEQ and FMX103 were developed using Molecule Stabilizing Technology, a proprietary foam platform designed to optimize the topical delivery of minocycline, an active pharmaceutical ingredient, that was available only in oral form until the FDA’s approval of AMZEEQ.
Foamix also licensed certain technology under development and licensing agreements to various pharmaceutical companies for development of certain products combining Foamix's foam technology with the licensee’s proprietary drugs.
In May 2014, Foamix incorporated a wholly-owned subsidiary in the United States of America - Foamix Pharmaceuticals Inc. (hereinafter referred to as the "Subsidiary"). The Subsidiary was incorporated to assist Foamix with regard to commercialization activities, regulatory affairs and business development relating to its pipeline and technology.
On November 10, 2019, Foamix entered into an Agreement and Plan of Merger (the "Merger Agreement") with Menlo Therapeutics, Inc. ("Menlo") and Giants Merger Subsidiary Ltd. (“Merger Sub”), a direct and wholly-owned subsidiary of Menlo. Under the terms of the agreement, Merger Sub agreed to merge with and into Foamix, with Foamix continuing as the surviving corporation and a wholly-owned subsidiary of Menlo (the “Merger”). On March 9, 2020, the Merger was completed and Foamix is now a wholly-owned subsidiary of Menlo, the legal acquirer. Foamix will cease to be a reporting company as of March 19, 2020 and all future filings of the combined company will be made by Menlo. As of the issuance of the financial statements, Foamix incurred transaction expenses in the amount of approximately $5.8 million.
At the effective time of the Merger (the “Effective Time”), each Foamix Ordinary Share, par value NIS 0.16 per share, issued and outstanding immediately prior to the Effective Time was exchanged for (i) 0.5924 shares (the “Exchange Ratio”) of common stock of Menlo and (ii) one contingent stock right (a “CSR”, and collectively, the “CSRs”). The CSRs are governed by the Contingent Stock Rights Agreement (the “CSR Agreement”), dated as of March 9, 2020, by and between Menlo and American Stock Transfer & Trust Company, LLC, and represent the non-transferable contractual right to receive shares of common stock of Menlo if specified events occur within agreed time periods. Pursuant to the CSR Agreement, each CSR may become convertible on May 31, 2020 or upon the occurrence of specified events relating to Menlo’s Phase III PN Trials, and, if so converted, will entitle its holder to receive from Menlo additional shares of Menlo common stock.
The Merger will be accounted in accordance with Accounting Standards Codification Topic 805, “Business Combinations,” using the acquisition method of accounting with Foamix as the accounting acquirer. Since Menlo, as the parent company of Foamix after the Merger, is the legal acquirer, the Merger will be accounted for as a reverse acquisition.
F-10
FOAMIX PHARMACEUTICALS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S. dollars in thousands, except share and per share amounts)
NOTE 1 - NATURE OF OPERATIONS (continued):
Since incorporation through December 31, 2019, Foamix and its subsidiary (hereinafter referred to as “the Company”) incurred losses and negative cash flows from operations mainly attributable to its development efforts and has an accumulated deficit of $310,587. The Company has financed its operations mainly through the issuance of shares through private and public financing rounds, debt financing, warrants and payments received pursuant to the terms of development and licensing agreements. As mentioned above, on March 9, 2020, the Merger with Menlo was completed. As of the issuance date of these financial statements, the Company's cash and investments, along with Menlo’s cash and investments, funds the Company may be entitled to receive upon reaching certain milestones under its credit agreement (see note 10) and the Company’s 2020 estimated income from AMZEEQ and FMX103, provide sufficient resources to fund its operations through at least the next 12 months. Prior to issuing these financial statements, the Company revised its operating plan in order to reduce expenses and, until it is able to obtain further funding, will only focus on (a) commercialization of AMZEEQ, (b) pre-commercialization and launch preparations for FMX103, assuming it receives regulatory approval, and (c) other general corporate expenses. In order to develop and commercialize any future product candidates if they are granted regulatory approval, the Company and Menlo (the “Combined Company”) may be required to obtain further funding through public or private offerings, debt financings, collaboration and licensing arrangements or other sources. Adequate additional funding may not be available to the Combined Company on acceptable terms, or at all. If the Combined Company is unable to raise capital when needed or on attractive terms, it may be forced to delay, reduce or eliminate its research and development programs or commercialization and manufacturing efforts.
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES:
| a. | Basis of presentation |
The Company’s financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”).
| b. | Use of estimates in the preparation of financial statements |
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. As applicable to these financial statements, the most significant estimates and assumptions relate to clinical trial accruals.
| c. | Functional currency |
The U.S. dollar (“dollar”) is the currency of the primary economic environment in which the operations of Foamix and the Subsidiary are conducted. Almost all Company revenues and operational expenses are in dollars and the Company’s financing has been provided in dollars. Accordingly, the functional currency of the Company is the dollar.
Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items in the statements of operations (indicated below), the following exchange rates are used: (i) for transactions - exchange rates at transaction dates or average rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization, etc.) - historical exchange rates. Currency transaction gains and losses are presented in financial income or expenses, as appropriate.
| d. | Principles of consolidation |
The consolidated financial statements include the accounts of Foamix and its Subsidiary. Intercompany balances and transactions including profits from intercompany sales not yet realized outside the Company, have been eliminated upon consolidation.
F-11
FOAMIX PHARMACEUTICALS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S. dollars in thousands, except share and per share amounts)
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):
| e. | Cash and cash equivalents |
The Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.
| f. | Bank deposits Bank deposits with original maturity dates of more than three months but at balance sheet date are less than one year are included in short-term deposits. The interest rates on the Company’s deposits range between 2.23%-3.15%. The fair value of bank deposits approximates the carrying value since they bear interest at rates close to the prevailing market rates. |
| g. | Marketable securities |
Marketable debt securities:
Marketable debt securities are classified as available for sale and are recorded at fair value. Management determines the appropriate classification of its investments in securities at the time of purchase. Classifications of debt securities in the balance sheet are determined based on the maturity date of the securities.
Dividend and interest income, including amortization of the premium and discount arising at acquisition, as well as realized gains and losses, are included in financial income.
Unrealized gains, net of taxes, are reflected in other comprehensive income (loss). Unrealized losses considered to be temporary are reflected in other comprehensive income (loss); unrealized losses that are considered to be other-than-temporary are charged to income as an impairment charge. Realized gains and losses are included in financial income, net.
Other-than-temporary impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the other-than-temporary impairment recognized in earnings, recorded in financial expense, net, is limited to the portion attributed to credit loss. The remaining portion of the other-than-temporary impairment related to other factors is recognized in other comprehensive income or loss.
Marketable equity securities:
The Company’s marketable equity securities are recorded at fair market value and, beginning January 1, 2018, following the adoption of ASU No. 2016-01, Financial Instruments—Overall (Subtopic 825-10), unrealized gains and losses are included in other income (expense), net in the consolidated statements of operations. Prior to January 1, 2018, unrealized gains, net of taxes, were reflected in other comprehensive income (loss) and unrealized losses were reflected in other comprehensive income (loss).
F-12
FOAMIX PHARMACEUTICALS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S. dollars in thousands, except share and per share amounts)
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):
| h. | Derivatives and Hedging |
The Company purchases foreign exchange derivative financial instruments (written and purchased currency options). The transactions are designed to hedge the Company’s currency exposure.
The Company recognizes all derivatives as either assets or liabilities in the consolidated balance sheet at their fair value. Changes
in the fair value of derivatives that are highly effective and designated as cash flow hedges are reported as a component of other
comprehensive income or loss and reclassified into earnings in the same line-item associated with the forecasted transaction and
in the same periods during which the hedged transaction impacts earnings.
For derivatives that qualify for hedge accounting, the cash flows associated with these derivatives are reported in the consolidated statements of cash flows consistently with the classification of cash flows from the underlying hedged items that these derivatives are hedging.
| i. | Inventory |
Prior to the date the Company obtains regulatory approval for its product candidates, inventory costs related to commercial production are expensed as research and development expense. Once regulatory approval is obtained, the Company capitalizes such costs as inventory. Inventories are stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first-out (“FIFO”) method. The Company periodically reviews its inventory levels and writes down inventory that is expected to expire prior to being sold, inventory in excess of expected sales requirements and inventory that fails to meet commercial sale specifications, with a corresponding charge to cost of goods sold.
| j. | Property and equipment |
1) Property and equipment are stated at cost, net of accumulated depreciation and amortization.
2)
The Company’s property and equipment are depreciated by the straight-line method on the basis of their estimated useful
life.
Annual rates of depreciation are as follows:
| % | ||||
| Computers | 15-33 | |||
| Laboratory equipment | 7-20 | |||
| Office furniture and equipment | 7-15 | |||
| Vehicles | 15 | |||
Leasehold improvements are amortized by the straight-line method over the expected lease term, which is shorter than the estimated useful life of the improvements.
F-13
FOAMIX PHARMACEUTICALS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S. dollars in thousands, except share and per share amounts)
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):
| k. | Impairment of long-lived assets |
The Company tests long-lived assets for impairment whenever events or circumstances present an indication of impairment. If the sum of expected future cash flows (undiscounted and without interest charges) of the assets is less than the carrying amount of such assets, an impairment loss would be recognized. The assets would be written down to their estimated fair values, calculated based on the present value of expected future cash flows (discounted cash flows), or some other fair value measure.
For the three years ended December 31, 2019, the Company did not recognize an impairment loss for its long-lived assets.
| l. | Allowance for doubtful accounts |
The Company performs ongoing credit evaluations to estimate the need for maintaining reserves for potential credit losses. An allowance for doubtful accounts is recognized on a specific basis with respect to those amounts that the Company has determined to be doubtful of collection. No allowance for doubtful accounts was recorded in the three years ended December 31, 2019.
| m. | Debt |
Debt discounts created as a result of the allocation of proceeds received from a debt issuance to warrants issued are amortized to interest expense under the effective interest method over the life of the recognized debt liability.
Debt issuance costs include the costs of debt financings undertaken by the Company, including legal fees and other direct costs of the financing. Debt issuance costs related to a recognized debt liability are presented on the consolidated balance sheet as a direct deduction from the carrying amount of the debt liability and are amortized to interest expense over the term of the related debt, using the effective interest method.
| n. | Leases |
In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2016-02, Leases (Topic 842), which supersedes the existing guidance for lease accounting, Leases (Topic 840). The new standard requires lessees to record assets and liabilities on the balance sheet for all leases. The Company elected the short-term lease recognition exemption for all leases with a term shorter than 12 months. Leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The Company recognizes the lease payments in the consolidated statements of operations on a straight-line basis over the lease period.
The Company adopted the standard as of January 1, 2019 on a modified retrospective basis and did not restate comparative periods. The Company elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed the Company to carryforward the historical lease classification and not separate lease and non-lease components for the leases.
F-14
FOAMIX PHARMACEUTICALS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S. dollars in thousands, except share and per share amounts)
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):
| o. | Contingencies |
Certain conditions may exist as of the date of the financial statements, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company’s management assesses such contingent liabilities and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.
Management applies the guidance in ASC 450-20-25 when assessing losses resulting from contingencies. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability is recorded as accrued expenses in the Company’s financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material are disclosed.
Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantees are disclosed.
| p. | Share-based compensation |
The Company accounts for employees’ and directors’ share-based payment awards classified as equity awards using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period using the straight-line method. Forfeitures are recognized as they occur.
Share-based payments related to the employee share purchase plan (“ESPP”) are recognized based on the fair value of each award estimated on the first day of the offering period and recognized as an expense over the offering period using the straight-line method.
The Company elected to recognize compensation costs for awards conditioned only on continued service that have a graded vesting schedule using the straight-line method based on the multiple-option award approach.
Prior to December 31, 2018, when options and restricted share units (hereinafter “RSUs”) were granted as consideration for services provided by nonemployees, the grants were accounted for based on the fair value of the consideration received or the fair value of the awards issued, whichever is more reliably measurable. The fair value of the awards granted was measured on a final basis at the end of the related service period and was recognized over the related service period using the straight-line method.
On January 1, 2019 the Company adopted the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718) Improvements to Nonemployee Share-based Payments. This ASU was issued to simplify the accounting for share-based transactions by expanding the scope of Topic 718 from only being applicable to share-based payments to employees to also include share-based payment transactions for acquiring goods and services from nonemployees. As a result, nonemployee share-based transactions are being measured by estimating the fair value of the equity instruments at the grant date, taking into consideration the probability of satisfying performance conditions.
F-15
FOAMIX PHARMACEUTICALS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S. dollars in thousands, except share and per share amounts)
NOTE 2−SIGNIFICANT ACCOUNTING POLICIES (continued):
| q. | Revenue recognition |
On January 1, 2018 the Company adopted ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). According to the standard, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the performance obligation is satisfied.
An entity only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer, after considering any price concession expected to be provided to the customer, when applicable. At contract inception, the entity assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The entity then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.
The adoption of the new standards did not change the Company’s revenue recognition as the majority of the Company’s revenues in the year ended December 31, 2019 and 2018, were driven from royalties from license agreements for products, developed combining the Company's foam technology with a drug selected by the licensee. The Company does not have future performance obligations under the license arrangements. The revenues are recorded based on the sales that occurred during the relevant period provided by licensees.
Prior to January 1, 2018 and before the adoption of the new standard, the Company's revenues also included development services driven from the development and license agreements. Revenue recognition from those agreements were recognized as follows:
The significant deliverables in the agreements between the Company and its licensees were the obligation of Company to provide development services and the grant of an exclusive license to the specific product developed. These deliverables were combined into one single unit of accounting for revenue recognition purposes since: (i) each element did not have value on a stand-alone basis; (ii) in order to develop the combined formulation in the licensed product, the use of the Company’s propriety technology was required. Therefore, the Company was the only party capable of performing the level and type of development services required under the agreement.
The Company’s development and license agreements entitle the Company to: (i) development payments, including upfront payments, cost reimbursements and payments contingent only upon passage of time (together, - “Development Service Payments”); (ii) payments contingent solely upon performance or achievement of clinical results by the Company’s licensees (“Contingent Payments”); (iii) royalties calculated as a percentage of sales of the developed the products made by the Company's licensees.
Revenues from Development Service Payments under development and license agreements were recognized as the services were provided. When the Company received a portion of the Development Service Payment before performance of such services, these advances were recorded as deferred revenues and recognized as revenues as services were performed. Contingent Payments were recognized when the licensee’s performance or achievement event occurred, and royalties were recognized when subsequent sales were made by the licensees.
F-16
FOAMIX PHARMACEUTICALS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S. dollars in thousands, except share and per share amounts)
NOTE 2−SIGNIFICANT ACCOUNTING POLICIES (continued):
| r. | Research and development costs |
Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of clinical trials, clinical trial supplies, salaries, share-based compensation expenses, payroll taxes and other employee benefits, lab expenses, consumable equipment and consulting fees. All costs associated with research and developments are expensed as incurred.
| s. | Clinical trial accruals |
Clinical trial expenses are charged to research and development expense as incurred. The Company accrues for expenses resulting from obligations under contracts with clinical research organizations (CROs). The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided. The Company’s objective is to reflect the appropriate trial expense in the consolidated financial statements by matching the appropriate expenses with the period in which services and efforts are expended. In the event advance payments are made to a CRO, the payments are recorded as other assets, which will be recognized as expenses as services are rendered.
| t. | Income taxes: |
| 1) | Deferred taxes |
Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than not that the deferred taxes will not be realized in the foreseeable future. Given the Company’s losses, the Company has provided a full valuation allowance with respect to its deferred tax assets.
| 2) | Uncertainty in income tax |
The Company follows a two-step approach in recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the available evidence indicates that it is more likely than not that the position will be sustained based on technical merits. If this threshold is met, the second step is to measure the tax position as the largest amount that has more than a 50% likelihood of being realized upon ultimate settlement.
F-17
FOAMIX PHARMACEUTICALS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S. dollars in thousands, except share and per share amounts)
| u. | Loss per share |
Net loss per share, basic and diluted, is computed on the basis of the net loss for the year divided by the weighted average number of Ordinary Shares outstanding during the year. Diluted net loss per share is based upon the weighted average number of Ordinary Shares and of Ordinary Shares equivalents outstanding when dilutive. Ordinary Share equivalents include outstanding share based payment arrangements and warrants which are included under the treasury share method when dilutive.
The following average share options, RSUs, warrants and incremental share to be issued under the ESPP were excluded from the calculation of diluted net loss per Ordinary Share because their effect would have been anti-dilutive for the year presented (share data):
| Year ended December 31 | ||||||||||||
| 2019 | 2018 | 2017 | ||||||||||
| Outstanding share options, RSUs and shares under ESPP | 6,115,124 | 4,684,916 | 3,657,612 | |||||||||
| Warrants | 467,123 | 508,154 | 1,498,718 | |||||||||
NOTE 2−SIGNIFICANT ACCOUNTING POLICIES (continued):
| v. | Fair value measurement |
Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:
| Level 1: | Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. | |
| Level 2: | Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar or identical assets or liabilities. | |
| Level 3: | Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. |
In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.
| w. | Concentration of credit risks |
Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents, restricted cash, bank deposits, marketable securities and certain receivables. The Company deposits cash and cash equivalents with highly rated financial institutions and, as a matter of policy, limits the amounts of credit exposure to any single financial institution. In addition, all marketable securities carry a high rating or are government insured. The Company has not experienced any material credit losses in these accounts and does not believe it is exposed to significant credit risk on these instruments.
F-18
FOAMIX PHARMACEUTICALS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S. dollars in thousands, except share and per share amounts)
| x. | Comprehensive loss |
Comprehensive loss includes, in addition to net loss, unrealized holding gains and losses on available-for-sale debt securities and derivative instruments designated as cash flow hedge (net of related taxes where applicable). For the year ended December 31, 2017, the comprehensive loss included also available-for-sale equity securities.
Reclassification adjustments for gain or loss of available for sales securities are included in finance expenses net in the statement of operations.
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):
| y. | Newly issued and recently adopted accounting pronouncements: |
Accounting pronouncements adopted in period:
| 1) | In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2016-02, Leases (Topic 842), which supersedes the existing guidance for lease accounting, Leases (Topic 840). The new standard requires lessees to record assets and liabilities on the balance sheet for all leases. The Company elected the short-term lease recognition exemption for all leases with a term shorter than 12 months. Leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. |
The adoption of the standard resulted in recognition of $1,357 of lease assets and lease liabilities as of January 1, 2019 on the Company’s consolidated balance sheets. The weighted-average interest rate used to discount future lease payments was 4.8%.
| 2) | On January 1, 2019 the Company adopted the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718) Improvements to Nonemployee Share-based Payments. This ASU was issued to simplify the accounting for share-based transactions by expanding the scope of Topic 718 from only being applicable to share-based payments to employees to also include share-based payment transactions for acquiring goods and services from nonemployees. As a result, nonemployee share-based transactions are being measured by estimating the fair value of the equity instruments at the grant date, taking into consideration the probability of satisfying performance conditions. The adoption of this slandered had no material impact on the Company’s consolidated financial statements. |
| 3) | In August 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-12, Derivatives and Hedging (Topic 815), Targeted Improvements to Accounting for Hedging Activities. Among other things, the guidance eliminated the requirement to separately measure and report hedge ineffectiveness and generally requires the entire change in the fair value of a hedging instrument to be presented in the same income statement line as the hedged item. As ASU 2017-12 was effective for fiscal years beginning after December 15, 2018, the Company adopted the ASU on January 1, 2019 with no material impact on the Company’s consolidated financial statements. |
F-19
FOAMIX PHARMACEUTICALS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S. dollars in thousands, except share and per share amounts)
NOTE 3 - FAIR VALUE MEASUREMENTS
The Company’s assets and liabilities that are measured at fair value as of December 31, 2019, and December 31, 2018, are classified in the tables below in one of the three categories described in note 2v above:
| December 31, 2019 | ||||||||||||
| Level 1 | Level 2 | Total | ||||||||||
| Marketable securities | $ | 1,020 | $ | 15,660 | $ | 16,680 | ||||||
| December 31, 2018 | ||||||||||||
| Level 1 | Level 2 | Total | ||||||||||
| Marketable securities | $ | 991 | $ | 46,229 | $ | 47,220 | ||||||
| Currency options designated as hedging instruments (current liability) | - | $ | (3 | ) | $ | (3 | ) | |||||
The Company’s debt securities are traded in markets that are not considered to be active, but are valued based on quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Accordingly, these assets are categorized as Level 2.
NOTE 3 - FAIR VALUE MEASUREMENTS (continued):
Foreign exchange risk management
Occasionally, the Company purchases and writes non-functional currency options in order to hedge the currency exposure on the Company’s cash flow. The currency hedged items are denominated in New Israeli Shekels (“NIS”). The purchasing and writing of options is part of a comprehensive currency hedging strategy with respect to salary and rent expenses denominated in NIS. These transactions are at zero cost for periods of up to one year. The counterparties to the derivatives are major banks in Israel. As of December 31, 2019, there were no hedged amounts.
As of December 31, 2019 and 2018, the Company has a lien in the amount of $290 on the Company’s marketable securities and a lien in the amount $250 on the Company’s checking account, in respect of bank guarantees granted in order to secure the hedging transactions.
F-20
FOAMIX PHARMACEUTICALS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S. dollars in thousands, except share and per share amounts)
NOTE 4 - MARKETABLE SECURITIES
Marketable securities as of December 31, 2019, and December 31, 2018 consist mainly of debt and mutual funds securities. The debt securities are classified as available-for-sale and are recorded at fair value. Changes in fair value, net of taxes (if applicable), are reflected in other comprehensive loss. Realized gains and losses on sales of the securities, as well as premium or discount amortization, are included in the consolidated statement of operations as finance income or expenses.
As of January 1, 2018, following the adoption of ASU No. 2016-01, Financial Instruments—Overall (Subtopic 825-10), equity securities with readily determinable fair value are measured at fair value. The changes in the fair value of equity investments are recognized through net income. Adoption of the standard was applied through a cumulative one-time adjustment of $35 to the accumulated deficit.
The following table sets forth the Company’s marketable securities:
| December 31 | ||||||||
| 2019 | 2018 | |||||||
| Israeli mutual funds | $ | 1,020 | $ | 991 | ||||
| Certificates of deposit | 151 | 2,773 | ||||||
| U.S Government and agency bonds | 6,031 | 25,215 | ||||||
| U.S Treasury bills | 9,478 | 18,241 | ||||||
| Total | $ | 16,680 | $ | 47,220 | ||||
At December 31, 2019 and 2018, the fair value, cost and gross unrealized holding gains and losses of the marketable securities owned by the Company were as follows:
| December 31, 2019 | ||||||||||||||||
| Fair value | Cost or Amortized cost | Gross unrealized holding loss | Gross unrealized holding gains | |||||||||||||
| Certificates of deposit | $ | 151 | $ | 151 | $ | - | $ | - | ||||||||
| U.S Government and agency bonds | 6,031 | 6,030 | - | 1 | ||||||||||||
| U.S Treasury bills | 9,478 | 9,475 | - | 3 | ||||||||||||
| Total | $ | 15,660 | $ | 15,656 | $ | - | $ | 4 | ||||||||
F-21
FOAMIX PHARMACEUTICALS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S. dollars in thousands, except share and per share amounts)
NOTE 4 - MARKETABLE SECURITIES (continued):
| December 31, 2018 | ||||||||||||||||
| Fair value | Cost or Amortized cost | Gross unrealized holding loss | Gross unrealized holding gains | |||||||||||||
| Israeli mutual funds | $ | 2,773 | $ | 2,790 | $ | 17 | $ | - | ||||||||
| Certificates of deposit | 25,215 | 25,236 | 22 | 1 | ||||||||||||
| U.S. Government and agency bonds | 18,241 | 18,243 | 3 | 1 | ||||||||||||
| Total | $ | 46,229 | $ | 46,269 | $ | 42 | $ | 2 | ||||||||
As of December 31, 2018, the unrealized losses attributed to the Company’s marketable securities were primarily due to credit spreads and interest rate movements. The Company has considered factors regarding other than temporary impaired securities and determined that there are no securities with impairment that is other than temporary as of December 31, 2018.
As of December 31, 2019, and 2018, the Company’s debt securities had the following maturity dates:
| Market value | ||||||||
| December 31 | ||||||||
| 2019 | 2018 | |||||||
| Due within one year | $ | 15,660 | $ | 46,079 | ||||
| 1 to 2 years | - | 150 | ||||||
| Total | $ | 15,660 | $ | 46,229 | ||||
During the years ended December 31, 2019 and 2018, the Company received proceeds of $49,819 and $32,247, respectively upon the sale and maturity of marketable securities.
$434 and $401 of the Company’s marketable securities were restricted as of December 31, 2019, and 2018, respectively, due to a lien in respect of bank guarantees granted to secure
hedging transaction and the Company’s rent agreement. Refer to note 7 and note 3.
NOTE 5 – INVENTORY
Inventories are stated at the lower of cost and net realizable value with cost determined on a first-in, first-out basis by product. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. The Company commenced capitalizing inventory for AMZEEQ upon FDA approval of AMZEEQ on October 18, 2019. No inventory was capitalized prior to October 18, 2019.
As of December 31, 2019, the Company’s inventory includes finished goods in the amount of $856, raw materials in the amount of $500 and no inventory write-down was recorded.
NOTE 6 - PROPERTY AND EQUIPMENT
| December 31 | ||||||||
| 2019 | 2018 | |||||||
| Cost: | ||||||||
| Leasehold improvements | $ | 1,052 | $ | 978 | ||||
| Computers and software | 646 | 515 | ||||||
| Laboratory equipment | 2,028 | 1,399 | ||||||
| Furniture | 391 | 245 | ||||||
| Vehicles | - | 82 | ||||||
| 4,117 | 3,219 | |||||||
| Less: | ||||||||
| Accumulated depreciation and amortization | 1,232 | 984 | ||||||
| Property and Equipment, net | $ | 2,885 | $ | 2,235 | ||||
F-22
FOAMIX PHARMACEUTICALS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S. dollars in thousands, except share and per share amounts)
NOTE 6 - PROPERTY AND EQUIPMENT (continued):
Depreciation and amortization expense totaled $350, $319 and $221 for the years ended December 31, 2019, 2018 and 2017, respectively.
During the years ended December 31, 2019, 2018 and 2017, the Company disposed of fixed assets in the net amount of $16, $42 and $104, respectively. Losses from sales of fixed assets for the years ended December 31, 2019, 2018 and 2017 were $2, $2 and $30, respectively.
NOTE 7 – OPERATING LEASE
The Company leases research and development facilities in Israel and executive offices in the United States under several lease agreements. The lease agreement for the facilities in Israel is linked to the Israeli consumer price index (“CPI”) and due to expire in December 2020.
On March 13, 2019, the Subsidiary signed an amendment to the original lease agreement for its facilities in the U.S. (“The Amendment”). The Amendment includes an extension of the lease period of the 10,000 square feet previously leased under the original agreement (the "Original Space") and an addition of 4,639 square feet (the "Additional Space”). The Subsidiary entered the Additional Space following a period of preparation by the lessor completed during September 2019 (the "Commencement Date"). The Amendment is due to expire on August 31, 2022.
Pursuant to The Amendment of the lease on the Current Space, the Company recognized an additional right of use asset and liability in the amount of $713. The Additional Space was considered a new lease agreement and was recognized as a right of use asset and liability, in the amount of $302, on the Commencement Date.
In July 2017, the Company entered into operating lease agreements in connection with the leasing of several vehicles. The lease periods are generally for three years and the payments are linked to the Israeli CPI. To secure the terms of the lease agreements, the Company has made certain prepayments to the leasing company, representing approximately three months of lease payments. These amounts have been recorded as part of the operating lease right to use assets.
Operating lease costs for the year ended December 31, 2019 are as follows:
| Year
Ended December 31 | ||||
| 2019 | ||||
| Office lease expenses | $ | 794 | ||
| Vehicles lease expenses | $ | 95 |
The operating lease costs include variable lease payments of $45.
Operating cash flows, for amounts included in the measurement of lease liabilities are as follows:
| Year Ended December 31 | ||||
| 2019 | ||||
| Office lease expenses | $ | 839 | ||
| Vehicles lease expenses | $ | 156 | ||
F-23
FOAMIX PHARMACEUTICALS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S. dollars in thousands, except share and per share amounts)
NOTE 7 – OPERATING LEASE (continued):
Supplemental information related to leases are as follows:
| December 31 | ||||
| 2019 | ||||
| Operating lease right-of-use assets | $ | 1,694 | ||
| Operating lease liabilities | $ | 1,745 | ||
| Weighted average remaining lease term | 1.93 | |||
| Weighted average discount rate | 6.08 | % | ||
Maturities of lease liabilities are as follows:
| 2020 | $ | 1,164 | ||
| 2021 | 455 | |||
| 2022 | 230 | |||
| Total lease payments | 1,849 | |||
| Less imputed interest | (104 | ) | ||
| Total lease liability | $ | 1,745 |
As of December 31, 2019, the Company had a lien in the amount of $144 on the Company’s marketable securities in respect of bank guarantees granted in order to secure the lease agreements.
Leases prior to the adoption of the new standard:
Operating lease expenses for the years ended December 31, 2018 and December 31, 2017 were $872 and $667 respectively.
Future minimum lease commitments under non-cancelable operating lease agreements according to ASC840, as of December 31, 2018 were as follows:
| 2019 | $ | 746 | ||
| 2020 | 682 | |||
| 2021 and thereafter | 21 | |||
| Total | $ | 1,449 |
F-24
FOAMIX PHARMACEUTICALS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S. dollars in thousands, except share and per share amounts)
NOTE 8 - EMPLOYEE SEVERANCE BENEFITS
The Company's liability for severance pay for its Israeli employees is calculated pursuant to Israeli severance pay law based on the most recent salary of the employee multiplied by the number of years of employment, as of the balance sheet date, less amounts funded in each employee’s severance fund. Such liability is recorded on the Company’s balance sheet under “Liability for employee severance benefits” as if it were payable at each balance sheet date on an undiscounted basis. The Company partially secures this liability by purchasing insurance policies or establishing dedicated severance accounts within the relevant employees’ pension funds, and making monthly deposits under such policies or into such accounts. The value of these policies is recorded as an asset in the Company's balance sheet.
During 2014, all of the Israeli employees agreed to the terms of Section 14 of the Israeli Severance Pay Law, 1963, according to which all deposits in the pension fund and/or with the insurance company, thereafter, exempt the Company from any additional obligation. These deposits are accounted as defined contribution payments and therefore not recorded on the Company’s balance sheet. Once the employees agreed to the terms of Section 14, all amounts funded on behalf of the employees were released to their full ownership. The liability for employee severance benefits as of December 31, 2019 and 2018, represents the Company's obligation that has not been secured by deposits to employee severance funds.
The amount of severance payment expenses to Israel employees were $719, $592 and $569 for the years ended December 31, 2019, December 31, 2018 and December 31, 2017, respectively.
Beginning September 2017, the Company has retirement savings plans available to all employees of the Subsidiary, which are intended to qualify as deferred compensation plans under Section 401(k) of the Internal Revenue Code (the “401(k) Plans”). The Company made contributions to these 401(k) Plans during the years ended December 31, 2019, 2018 and 2017 of approximately $203, $84 and $35, respectively.
During 2020, the Company expects to deposit approximately $1,014 with respect to employee’s severance benefits.
NOTE 9 – COMMITMENTS AND CONTINGENCIES
Litigation and contingencies
Seven lawsuits have been filed in the U.S. against the Company in connection with the Merger. The lawsuits generally allege that the registration statement on Form S-4 and the prospectus/joint proxy statement included therein included false or misleading information regarding the Merger in violations of Section 14(a) and Section 20(a) of the Exchange Act and/or Rule 14a 9 promulgated under the Exchange Act. In addition, one of the lawsuits alleges that the members of the Company’s board of directors breached their fiduciary duties in connection with the Merger. The plaintiffs are seeking, among other things, to enjoin consummation of the Merger, or alternatively rescission or rescissory damages; to compel the individual defendants to disseminate a joint proxy statement/prospectus that does not contain any untrue statements of material fact and that states all material facts required in it or necessary to make the statements contained therein not misleading; a declaration that defendants violated Sections 14(a) and/or 20(a) of the Exchange Act; a declaration that the Merger Agreement was entered into in breach of fiduciary duty and is therefore invalid and unenforceable; an order directing the individual defendants to commence a sale process for the Company and obtain a transaction; and an award of costs, including attorneys’ and experts’ fees and expenses, as well as an accounting of damages allegedly suffered by the plaintiffs. The Company believes the lawsuits are without merit and intend to defend vigorously against all claims asserted and it is management’s view that the financial statements include an adequate provision in respect of the claims.
F-25
FOAMIX PHARMACEUTICALS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S. dollars in thousands, except share and per share amounts)
NOTE 10 - LONG-TERM DEBT
On July 29, 2019 (the “Closing Date”) the Company secured up to $50 million in debt from two of its current shareholders, who are considered related parties (the “lenders”) and entered into a Securities Purchase Agreement with one of the lenders for gross proceeds of approximately $14 million, before deducting offering expenses (see Note 11).
The debt consists of term loans under a credit agreement (the “Credit Agreement”) and comprises of three trenches: (a) $15 million funded at closing (the “Tranche 1 Loan”), (b) $20 million funded on December 17, 2019 (the “Tranche 2 Loan”) and (c) up to $15 million available after the closing date and prior to September 30, 2020 (the “Tranche 3 Loan”). The Tranche 2 Loan was borrowed following the FDA’s approval of the Company’s NDA for AMZEEQ (formerly known as FMX101) and listing of AMZEEQ in the FDA’s “Orange Book,” in addition to maintained its arrangements with a third party for the commercial supply and manufacture of AMZEEQ. The Company shall be permitted to borrow the Tranche 3 Loan only following the achievement of certain revenue targets. Subject to any acceleration as provided in the Credit Agreement, including upon an event of default (as defined in the Credit Agreement), the credit facility will mature on July 29, 2024 and bear interest equal to the sum of (A) 8.25% (subject to increase in accordance with the terms of the Credit Agreement) plus (B) the greater of (x) the one-month LIBOR as of the second business day immediately preceding the first day of the calendar month or the date of borrowing (if such loan is not outstanding as of the first day of the calendar month), as applicable, and (y) 2.75%. A fee in an amount equal to 1.0% of the aggregate principal amount of all loans made on any given borrowing date shall be payable to the lenders.
The Credit Agreement is secured by a first-priority lien and security interest in substantially all of the Company’s tangible and intangible assets including intellectual property.
The Credit Agreement contains certain financial covenants, including that the Company (1) at all times after the date of FDA approval of AMZEEQ maintain a minimum aggregate compensating cash balance of $2.5 million; and (2) as of the last day of each fiscal quarter commencing on the fiscal quarter ending September 30, 2020, receive revenue for the trailing 12-month period in amounts set forth in the Credit Agreement, which range from $10.5 million for the fiscal quarter ending September 30, 2020 to $109.5 million for the fiscal quarter ending September 30, 2024.
As of December 31, 2019, the Company is in compliance with all covenants, including maintaining a minimum aggregate compensating cash balance as mentioned above. In the event where the Company fails to observe or perform any of the financial covenants the lenders may, by notice to the Company, declare the Term Loans then outstanding to be due and payable in whole, together with accrued interest and a Prepayment Premium (as defined in the Credit Agreement).
Under the Credit Agreement, there are no required payments of principal amounts until July 2023. Afterwards, the Company will pay 1.5% of the aggregate principal amount each month. The outstanding amount will be paid in full on July 2024.
In addition to the Credit Agreement, on the Closing Date, the Company issued to the lenders warrants to purchase up to an aggregate of 1,100,000 of its Ordinary Shares, at an exercise price of $2.09 per share (the “Warrant”), which represents the five-day volume weighted average price of the Ordinary Shares as of the trading day immediately prior to the Closing Date. Payment of the exercise price will be made, at the option of the lender, either in cash or as a reduction of Ordinary Shares issuable upon exercise of the Warrant, with an aggregate fair value equal to the aggregate exercise price ("cashless exercise"), or any combination of the foregoing. The Warrants were exercisable immediately following the closing of the Credit Agreement and are due to expire on July 29, 2026. Any Warrants left outstanding will be cashless exercised on the Warrants' expiration date, if in the money. The Warrants issued were classified as equity in accordance with ASC 815-40. Proceeds received under the Tranche 1 Loan were allocated to the Warrants and the Tranche 1 Loan on a relative fair value basis.
F-26
FOAMIX PHARMACEUTICALS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S. dollars in thousands, except share and per share amounts)
NOTE 10 – LONG-TERM DEBT (continued):
The company incurred offering expenses of $1,090 in connection with transactions contemplated by the Credit Agreement and the Securities Purchase Agreement, which were allocated to the Warrants, shares and debt consistently with the allocation of proceeds. The Company incurred additional expenses in the amount of $293 from the borrowing of Tranche 2 Loan, allocated only to the debt.
Debt issuance costs are recorded on the consolidated balance sheet as a reduction of liabilities.
Amounts allocated to the debt, net of issuance cost, are subsequently recognized at amortized cost using the effective interest method.
The fair value of the debt as of December 31, 2019 was $36.6 million and is categorized as Level 3. The valuation was performed by applying the income approach, under which the contractual present value method was used. The estimation of risk adjusted discount curve was based on public information reported in the financial statements of publicly traded venture lending companies.
During the year ended December 31, 2019 the company recorded finance expense of $802 and $119 relating to the interest and discount cost, respectively.
NOTE 11 - SHARE CAPITAL:
| a. | Rights of the Company’s Ordinary Shares |
Each Ordinary Share is entitled to one vote. The holders of Ordinary Shares are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors. Since its inception, the Company has not declared any dividends.
Following the Merger (see Note 1) Ordinary Shares were deemed transferred to Menlo in exchange for the right to receive (i) 0.5924 shares of common stock of Menlo Common Stock and (ii) one CSR. All outstanding Options and RSUs were converted using the Exchange Ratio and exercise price of the new options will be calculated by dividing the old exercise price by the Exchange Ratio. The Exchange Ratio is subject to adjustment based on the outcome and timing of the top-line primary endpoint results of one or both Melo’s Phase III double-blinded, placebo-controlled trials for the treatment of pruritus associated with prurigo nodularis, referenced by Protocol Numbers MTI-105 (United States) and MTI-106 (Europe).
| b. | Warrants |
In May and June 2014, the Company issued to certain investors Warrant to purchase Ordinary Shares at an exercise price of $5.04 per share or through a cashless exercise. As defined in the warrant agreements, the Warrants were exercisable until May 13, 2018. On that date all outstanding warrants were automatically exercised by the Warrant holders on a net issuance basis.
In addition to the Credit Agreement signed on July 29, 2019, on the Closing Date, the Company issued to the lender Warrants to purchase up to an aggregate of 1,100,000 of its Ordinary Shares. The warrants were exercisable immediately following the closing of the Credit Agreement and are due to expire on July 29, 2026. Any Warrants left outstanding will be cashless exercised on the Warrants' expiration date, if in the money.
During the years ended December 31, 2018, and 2017 1,394,558 and 413,242 warrants were exercised into 178,468 and 191,793 Ordinary Shares, respectively. During the year ended December 31, 2019 no Warrant were exercised.
F-27
FOAMIX PHARMACEUTICALS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S. dollars in thousands, except share and per share amounts)
NOTE 11 - SHARE CAPITAL (continued):
| c. | Public offerings |
On September 18, 2018, the Company completed a public offering in which 11,670,000 Ordinary Shares were sold at a price of $6.00 per share. Upon closing of the offering, the underwriters exercised their ‘green shoe’ option at full and purchased 1,750,500 additional Ordinary Shares. The net proceeds, including the underwriters' option, were approximately $75,356, after deducting underwriter’s discounts, commissions and other offering expenses.
| d. | Securities Purchase Agreement |
On April 13, 2018, the Company entered into a Securities Purchase Agreement with an existing investor pursuant to which the Company agreed to issue and sell, in a registered offering, an aggregate of 2,940,000 Ordinary Shares at a purchase price of $5.50 per share. The net proceeds from the offering were $16,131 after deducting transaction expenses. The closing of the issuance and sale of these shares took place on April 16, 2018.
On July 29, 2019, pursuant to the Credit Agreement and Securities Purchase Agreement, the Company issued and sold, in a registered offering, an aggregate of 6,542,057 shares of the Company’s Ordinary Shares, at a purchase price of $2.14 per share, representing the closing share price on the last trading day prior to signing, for aggregate gross proceeds of approximately $14 million, before deducting issuance costs allocated as described in Note 10 above, in the amount of $286.
| e. | Share Based Compensation |
Equity incentive plan:
On April 10, 2019, the Company's shareholders approved a new equity incentive plan (the "Plan") replacing the prior equity plans approved in 2015 and 2009. The Plan included a pool of 6,027,990 Ordinary Shares for grant to Company employees, consultants, directors and other service providers. As of December 31, 2019, 5,215,508 shares remain available for grant under the Plan.
Employee Share Purchase Plan:
On April 10, 2019 the Company’s shareholders approved an ESPP pursuant to which qualified employees (as defined in the ESPP) may elect to purchase designated shares of the Company’s Ordinary Shares at a price equal to 85% of the lesser of the fair market value of Ordinary Shares at the beginning or end of each semi-annual share purchase period (“Purchase Period”). Employees are permitted to purchase the number of shares purchasable with up to 15% of the earnings paid (as such term is defined in the ESPP) to each of the participating employees during the Purchase Period, subject to certain limitations under Section 423 of the U.S. Internal Revenue Code.
The number of Ordinary Shares initially reserved for purchase under the ESPP was 5,400,000 Ordinary Shares. As of December 31, 2019, 5,265,551 shares remain available for grant under the ESPP.
During the year ended December 31, 2019 134,449 shares were issued to the employees.
F-28
FOAMIX PHARMACEUTICALS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S. dollars in thousands, except share and per share amounts)
NOTE 11 - SHARE CAPITAL (continued):
Options and RSUs granted to employees and directors:
In the years ended December 31, 2019, 2018 and 2017, the Company granted options as follows:
| Year ended December 31, 2019 | ||||||||||||||
| Award amount | Exercise price range | Vesting period | Expiration | |||||||||||
| Employees and Directors: | ||||||||||||||
| Options | 1,635,296 | $2.36- $3.88 | 1 year -4 years | 10 years | ||||||||||
| RSU | 425,604 | - | 1 year -4 years | - | ||||||||||
| Year ended December 31, 2018 | ||||||||||||||
| Award
amount | Exercise price range | Vesting period | Expiration | |||||||||||
| Employees and Directors: | ||||||||||||||
| Options | 895,903 | $4.06- $6.40 | 1 year -4 years | 10 years | ||||||||||
| RSU | 216,673 | - | 3 year -4 years | - | ||||||||||
| Year ended December 31, 2017 | ||||||||||||||
| Award
amount | Exercise price range | Vesting period | Expiration | |||||||||||
| Employees and Directors: | ||||||||||||||
| Options | 1,352,267 | $4.69- $10.31 | 4 years | 10 years | ||||||||||
| RSU | 370,091 | - | 4 years | - | ||||||||||
The fair value of options and RSUs granted during 2019, 2018 and 2017 was $4,394, $3,953 and $8,510, respectively.
The fair value of each option granted is estimated using the Black-Scholes option pricing method. The volatility is based on a combination of the Company’s historical volatility, historical volatilities of companies in comparable stages as well as companies in the industry, by statistical analysis of daily share pricing model. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected term of the options granted in dollar terms. The Company’s management uses the expected term of each option as its expected life. The expected term of the options granted represents the period of time that granted options are expected to remain outstanding.
The fair value of RSUs granted to employees and directors is based on the share price on grant date and was computed using the Black-Scholes model.
F-29
FOAMIX PHARMACEUTICALS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S. dollars in thousands, except share and per share amounts)
NOTE 11 - SHARE CAPITAL (continued):
The underlying data used for computing the fair value of the options are as follows:
| Year ended December 31 | ||||||||||||
| 2019 | 2018 | 2017 | ||||||||||
| Value of ordinary share | $2.66-$3.88 | $4.09-$5.99 | $4.44-$10.12 | |||||||||
| Dividend yield | 0% | 0% | 0% | |||||||||
| Expected volatility | 59.35%-61.4% | 61%-62.6% | 58.41%-61.7% | |||||||||
| Risk-free interest rate | 1.42%-2.62% | 2.75%-2.87% | 1.97%-2.16% | |||||||||
| Expected term | 6 years | 6 years | 6 years | |||||||||
Options and RSUs granted to consultants and service providers:
During the years ended December 31, 2019 and 2018 there were no grants of options and RSUs to consultants and service providers.
In the year ended December 31, 2017, the Company granted options as follows:
| Year ended December 31, 2017 | ||||||||||||
| Award amount | Exercise
price range | Vesting
period | Expiration | |||||||||
| Options | 4,800 | $ | 6.34 | 4 years | 10 years | |||||||
The total unrecognized share-based compensation cost at December 31, 2019 is $7,220, which is expected to be recognized over a weighted average period of two years.
Modification of share-based compensation:
During the year ended December 31, 2017 the Company performed a Type III modification for share-based compensation due to the retention of the options and RSUs for several employees (including Dr. Dov Tamarkin, former Chief Executive Officer and Mr. Meir Eini, Chief Innovation Officer) who have become consultants to the Company. As a result of the modification, during the year ended December 31, 2017, the Company reversed all expense previously recorded for these retained awards in the amount of $2,037 and recorded the additional compensation expense in the amount of $1,058 over the new requisite service period.
During the year ended December 31, 2018 the Company recorded additional share-based compensation expenses in the amount of approximately $690 with respect to Type III modification.
F-30
FOAMIX PHARMACEUTICALS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S. dollars in thousands, except share and per share amounts)
NOTE 11 - SHARE CAPITAL (continued):
Summary of outstanding and exercisable options and RSUs:
The following table summarizes the number of options outstanding for the years ended December 31, 2019, December 31, 2018 and December 31, 2017, and related information:
| Employees and directors | Consultants
and service providers | |||||||||||||||
| Number
of options | USD(1) | Number
of options | USD(1) | |||||||||||||
| Outstanding at January 1, 2017 | 2,377,092 | $ | 5.87 | 137,050 | $ | 2.81 | ||||||||||
| Granted | 1,352,267 | 7.47 | - | - | ||||||||||||
| Forfeited | (39,213 | ) | 7.93 | (8,800 | ) | 8.40 | ||||||||||
| Exercised | (61,881 | ) | 2.63 | - | - | |||||||||||
| Re-designated(2) | (252,210 | ) | 7.71 | 252,210 | 7.71 | |||||||||||
| Outstanding at December 31, 2017 | 3,376,055 | $ | 6.41 | 380,460 | $ | 5.93 | ||||||||||
| Granted | 895,903 | 5.61 | - | - | ||||||||||||
| Forfeited | (150,240 | ) | 7.98 | (41,697 | ) | 8.12 | ||||||||||
| Exercised | (24,625 | ) | 1.92 | (67,500 | ) | 0.05 | ||||||||||
| Outstanding at December 31, 2018 | 4,097,093 | $ | 6.20 | 271,263 | $ | 7.05 | ||||||||||
| Granted | 1,635,296 | 3.39 | - | - | ||||||||||||
| Forfeited | (72,278 | ) | 6.78 | (15,625 | ) | 7.98 | ||||||||||
| Exercised | (298,682 | ) | 1.12 | (18,125 | ) | 1.31 | ||||||||||
| Re-designated(2) | (46,662 | ) | 7.58 | 46,662 | 7.58 | |||||||||||
| Outstanding at December 31, 2019 | 5,314,767 | $ | 5.60 | 284,175 | $ | 7.45 | ||||||||||
| (1) | Weighted average price per share |
| (2) | Pursuant to change in status of grantees from ‘employee’ and ‘director’ to ‘consultant’ during the reporting period. |
The following table summarizes the number of RSUs outstanding for the years ended December 31, 2019, December 31, 2018 and December 31, 2017:
| Employees
and directors | Consultants
and service providers | |||||||
| Number of RSUs | ||||||||
| Outstanding at January 1, 2017 | 142,683 | 42,050 | ||||||
| Awarded | 370,091 | - | ||||||
| Forfeited | (4,025 | ) | (550 | ) | ||||
| Vested | (43,038 | ) | (33,625 | ) | ||||
| Re-designated(1) | (78,120 | ) | 78,120 | |||||
| Outstanding at December 31, 2017 | 387,591 | 85,995 | ||||||
| Awarded | 216,673 | - | ||||||
| Forfeited | (11,746 | ) | (12,150 | ) | ||||
| Vested | (161,648 | ) | (60,271 | ) | ||||
| Outstanding at December 31, 2018 | 430,870 | 13,574 | ||||||
| Awarded | 425,604 | - | ||||||
| Forfeited | (9,159 | ) | - | |||||
| Vested | (225,687 | ) | (10,405 | ) | ||||
| Re-designated(1) | (10,199 | ) | 10,199 | |||||
| Withholding of shares | (9,775 | ) | - | |||||
| Outstanding at December 31, 2019 | 601,654 | 13,368 | ||||||
| (1) | Pursuant to change in status of grantees from ‘employee’ and ‘director’ to ‘consultant’ during the reporting period. |
F-31
FOAMIX PHARMACEUTICALS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S. dollars in thousands, except share and per share amounts)
NOTE 11 - SHARE CAPITAL (continued):
The following tables summarizes information concerning outstanding and exercisable options as of December 31, 2019:
| December 31, 2019 | |||||||||||||||||
| Options outstanding | Options exercisable | ||||||||||||||||
| Number of | Weighted | Number of | Weighted | ||||||||||||||
| options | Average | options | Average | ||||||||||||||
| Exercise | outstanding | Remaining | exercisable | Remaining | |||||||||||||
| prices per | at end of | Contractual | at end of | contractual | |||||||||||||
| share (USD) | year | Life | year | Life | |||||||||||||
| 1.92-3.88 | 1,723,515 | 8.91 | 234,749 | 6.34 | |||||||||||||
| 4.06-6.18 | 1,526,944 | 7.24 | 1,024,250 | 6.90 | |||||||||||||
| 6.30-7.98 | 1,682,087 | 6.17 | 1,406,840 | 5.83 | |||||||||||||
| 8.55-11.87 | 666,396 | 6.50 | 506,540 | 6.30 | |||||||||||||
| 5,598,942 | 3,172,379 | ||||||||||||||||
The aggregate intrinsic value of the total of both the outstanding and exercisable options as of December 31, 2019, is $721.
Share-based compensation expenses:
The following table illustrates the effect of share-based compensation on the statements of operations:
| Year ended December 31 | ||||||||||||
| 2019 | 2018 | 2017 | ||||||||||
| Cost of revenues | $ | - | $ | - | $ | 2 | ||||||
| Research and development expenses | 1,564 | 2,054 | 1,711 | |||||||||
| Selling, general and administrative | 3,331 | 3,266 | 2,453 | |||||||||
| $ | 4,895 | $ | 5,320 | $ | 4,166 | |||||||
NOTE 12 - INCOME TAX:
The Company is taxed under Israel and the United States of America tax laws:
| a. | Tax rates: |
| 1) | Income from Israel was taxed at the corporate tax rate of 24% in 2017 and 23% in 2018 and thereafter. |
| 2) | Effective January 1, 2018, the U.S. Tax Cuts and Jobs Act, reduced the U.S. federal statutory tax rate from 35% in 2017 to 21%. |
| b. | Tax assessments |
Foamix has tax assessments that are considered to be final through tax year 2014.
| c. | Tax benefits under the Law for Encouragement of Industry (Taxation), 1969 |
Foamix believes that it currently qualifies as an "Industrial Company" under the above law. As such it is entitled to certain tax benefits, mainly the right to deduct share issuance costs over three years for tax purposes in the event of a public offering.
Foamix utilizes this tax benefit.
F-32
FOAMIX PHARMACEUTICALS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S. dollars in thousands, except share and per share amounts)
NOTE 12 - INCOME TAX (continued):
| d. | Loss before income tax taxes: |
Loss (income) before income taxes is composed of the following:
| Year ended December 31 | ||||||||||||
| 2019 | 2018 | 2017 | ||||||||||
| Foamix Pharmaceuticals Ltd | $ | 66,747 | $ | 71,925 | $ | 64,952 | ||||||
| Foamix Pharmaceuticals Inc | 28,607 | 2,026 | (401 | ) | ||||||||
| Total Loss before taxes | $ | 95,354 | $ | 73,951 | $ | 64,551 | ||||||
| e. | Losses for tax purposes carried forward to future years |
As of December 31, 2019, Foamix had approximately $224.4 million and $27.3 million of net carry forward tax losses in Israel and the U.S., respectively, which are available to reduce future taxable income with no limited period of use.
During the year ended December 31, 2019 the U.S. Subsidiary incurred tax income of $176. During the years ended December 31, 2018 and 2017, the U.S. Subsidiary incurred a tax expense in the amount of $212 and $1,164, respectively.
| f. | Deferred income taxes: |
| December 31, | ||||||||
| 2019 | 2018 | |||||||
| In respect of: | ||||||||
| Net operating loss carry forward | $ | 59,241 | $ | 33,859 | ||||
| Research and development | 10,089 | 12,932 | ||||||
| Share based compensation | 1,446 | 957 | ||||||
| Other | 225 | 164 | ||||||
| Less - valuation allowance | (71,001 | ) | (47,912 | ) | ||||
| Net deferred tax assets | $ | - | $ | - | ||||
Realization of deferred tax assets is contingent upon sufficient future taxable income during the period that deductible temporary differences and carry forward losses are expected to be available to reduce taxable income. As the achievement of required future taxable income is not likely, the Company recorded a full valuation allowance.
As of December 31, 2019, the Company had no intention of realizing its investment in the Subsidiary and therefore deferred taxes have not been provided on taxes that would apply in the event of disposal of the investments.
Foamix may incur an additional tax liability in the event of an inter-company dividend distribution from its Subsidiary; no additional deferred taxes have been provided, since it is the Company’s policy not to distribute in the foreseeable future, dividends which would result in additional tax liability.
F-33
FOAMIX PHARMACEUTICALS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S. dollars in thousands, except share and per share amounts)
NOTE 12 - INCOME TAX (continued):
Following is a reconciliation of the theoretical tax benefit, assuming all income is taxed at the statutory corporate tax rate applicable to Israeli corporations, and the actual tax expense:
| Year ended December 31 | ||||||||||||
| 2019 | 2018 | 2017 | ||||||||||
| Loss before income taxes | $ | 95,354 | $ | 73,951 | $ | 64,551 | ||||||
| Theoretical tax benefit on the above amount | (21,931 | ) | (17,009 | ) | (15,492 | ) | ||||||
| Decrease (increase) in tax refund resulting from: | ||||||||||||
| Reduction and different corporate tax rates | (1,430 | ) | (101 | ) | 711 | |||||||
| Non-deductible expenses and other permanent differences, mainly share based compensation expenses and issuance costs | 225 | (84 | ) | 80 | ||||||||
| Uncertain tax position | (176 | ) | (98 | ) | 988 | |||||||
| Net change in valuation allowance | 23,089 | 17,063 | 14,858 | |||||||||
| Other | 47 | 441 | 19 | |||||||||
| Actual tax expense | $ | (176 | ) | $ | 212 | $ | 1,164 | |||||
| g. | Uncertain tax positions: |
ASC No. 740, Income Taxes, requires significant judgment in determining what constitutes an individual tax position as well as assessing the outcome of each tax position. Changes in judgment as to recognition or measurement of tax positions can materially affect the estimate of the effective tax rate and consequently, affect the operating results of the Company.
The following table summarizes the activity of the Company unrecognized tax benefits:
| Balance at January 1, 2018 | $ | 988 | ||
| Decrease in uncertain tax positions for the year | (98 | ) | ||
| Balance at December 31, 2018 | $ | 890 | ||
| Decrease in uncertain tax positions for the year | (176 | ) | ||
| Balance at December 31, 2019 | $ | 714 |
| h. | Roll forward of valuation allowance: |
| Balance at January 1, 2017 | $ | 15,991 | ||
| Additions | 14,858 | |||
| Balance at December 31, 2017 | $ | 30,849 | ||
| Additions | 17,063 | |||
| Balance at December 31, 2018 | $ | 47,912 | ||
| Additions | 23,089 | |||
| Balance at December 31, 2019 | $ | 71,001 |
F-34
FOAMIX PHARMACEUTICALS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S. dollars in thousands, except share and per share amounts)
NOTE 13 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION:
Balance sheets:
| a. | Other current assets: |
| December 31 | ||||||||
| 2019 | 2018 | |||||||
| Institutions | $ | 471 | $ | 446 | ||||
| Prepaid expenses | 1,038 | 450 | ||||||
| Other | 48 | 103 | ||||||
| $ | 1,557 | $ | 999 | |||||
Statements of operations:
| b. | Revenues |
The Company is entitled to royalty payments with respect to sales of a product developed by a customer in collaboration with the Company (“the Product”).
During 2018, a new customer acquired the Product and assumed all rights and responsibilities under the initial agreement.
As of December 31, 2019, the Company has yet to record revenues from the sale of AMZEEQ.
The following table provides a breakdown of the Company’s net revenues:
| Year ended December 31 | ||||||||||||
| 2019 | 2018 | 2017 | ||||||||||
| Development Service Payments | $ | - | $ | 62 | $ | 140 | ||||||
| Royalties | 443 | 3,533 | 3,529 | |||||||||
| Total revenues | $ | 443 | $ | 3,595 | $ | 3,669 | ||||||
| c. | Finance income and expenses: |
| Year ended December 31 | ||||||||||||
| 2019 | 2018 | 2017 | ||||||||||
| Finance expenses: | ||||||||||||
| Interest and finance expenses on long-term debt | $ | 921 | $ | - | $ | - | ||||||
| Foreign exchange losses, net | 213 | 27 | 57 | |||||||||
| Other expenses | 19 | 17 | 14 | |||||||||
| Total finance expenses | 1,153 | 44 | 71 | |||||||||
| Finance income: | ||||||||||||
| Gains from securities, net | (1,083 | ) | (688 | ) | (602 | ) | ||||||
| Interest on bank deposits | (589 | ) | (297 | ) | (532 | ) | ||||||
| Total finance income | $ | (1,672 | ) | $ | (985 | ) | $ | (1,134 | ) | |||
F-35
FOAMIX PHARMACEUTICALS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S. dollars in thousands, except share and per share amounts)
NOTE 14 - ENTITY-WIDE DISCLOSURE:
Revenues from principal customers - revenues from single customers that exceed 10% of total revenues in the relevant year:
| Year ended December 31 | ||||||||||||
| 2019 | 2018 | 2017 | ||||||||||
| Customer A | $ | - | $ | 2,467 | $ | 3,529 | ||||||
| Customer B | $ | 443 | $ | 1,066 | $ | - | ||||||
NOTE 15 – MENLO MERGER
On March 9, 2020, the Merger of Foamix with Menlo Merger Sub was completed, and the Company is now a wholly-owned subsidiary of Menlo, the legal acquirer (See note 1).
The Merger will be accounted in accordance with Accounting Standards Codification Topic 805, “Business Combinations”, using the acquisition method of accounting with Foamix as the accounting acquirer. Since Menlo, as the parent company of Foamix after the Merger, is the legal acquirer, the Merger will be accounted for as a reverse acquisition.
As the Merger was completed subsequent to December 31, 2019, the consolidated financial statements do not include the results or the financial position of Menlo.
Under the disclosure requirements of ASC 805 the Company is required to provide information regarding the effect of the business combination.
Due to the following limitations, the initial accounting for the business combination was incomplete at the time of the issuance of the financial statements, therefore, the Company did not include the above mentioned information as permitted by ASC 805-10-50-4 and ASC 805-30-50-3.
| 1) | As described above, the acquisition was completed on March 9, 2020, while the filing date the Company’s annual financial statements in form 10-K is March 12, 2020. |
| 2) | Full and final financial data of Menlo was available to the Company only on March 3, 2020 following the filing of Menlo’s form 10-K. |
| 3) | The Company hasn’t completed the work of the purchase price allocation needed under ASC 805. |
F-36
Exhibit 99.2
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
The following unaudited pro forma condensed combined financial information is presented to illustrate the estimated effects of the merger transaction involving Menlo Therapeutics Inc. (“Menlo”) and Foamix Pharmaceiticals Ltd. (“Foamix”) as described below.
On November 10, 2019, Menlo entered into an Agreement and Plan of Merger (as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated as of December 4, 2019, the “Merger Agreement”) with Foamix, and Giants Merger Subsidiary Ltd. (“Merger Sub”), a direct and wholly-owned Israeli subsidiary of Menlo, whereby Merger Sub agreed to merge with and into Foamix, with Foamix continuing as the surviving corporation and a wholly-owned subsidiary of Menlo (the “Merger”).
On March 9, 2020 (the “Effective Date”), the Merger was completed and Foamix is now a wholly-owned subsidiary of Menlo. Foamix ceased to be an SEC reporting company as of March 19, 2020 and all future SEC filings of the combined company will be made by Menlo.
On the Effective Date, each ordinary share of Foamix was exchanged for 0.5924 shares of common stock of Menlo (the “Exchange Ratio”). In addition, on the Effective Date, Foamix shareholders received one contingent stock right (“CSR”) for each Foamix ordinary share held by them. The CSRs were issued pursuant to the Contingent Stock Rights Agreement (the “CSR Agreement”), dated as of March 9, 2020, by and between Menlo and American Stock Transfer & Trust Company, LLC, and represented the non-transferable contractual right to receive shares of common stock of Menlo depending on the results of Menlo’s phase 3 clinical trials evaluating the safety and efficacy of once daily oral serlopitant for the treatment of prurigo nodularis (the “Phase III PN Trials”).
As previously disclosed by Menlo in its Current Report on Form 8-K filed with the SEC on April 6, 2020, each of Menlo’s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. Accordingly, pursuant to the terms of the CSR Agreement, each CSR was converted into 1.2082 shares of Menlo common stock, resulting in an effective Exchange Ratio in the Merger of 1.8006 shares of Menlo common stock for each Foamix ordinary share. Following the delivery of the shares of Menlo common stock underlying the CSRs, pre-Merger Foamix shareholders and pre-Merger Menlo stockholders own approximately 82% and 18% of post-Merger Menlo, respectively. The following unaudited pro forma condensed combined financial information does not give effect to the reported Phase III Trial results and CSR conversion.
The below unaudited pro forma condensed combined balance sheet as of December 31, 2019 combines the historical audited balance sheets of Menlo and Foamix as of December 31, 2019, giving effect to the Merger as if it had been consummated on December 31, 2019. The below unaudited pro forma condensed combined statement of operations and comprehensive loss for the year ended December 31, 2019 gives effect to the Merger as if it had been consummated on January 1, 2019. The unaudited pro forma condensed combined financial information also gives effect to the assumptions and adjustments described in the accompanying notes to the unaudited pro forma condensed combined financial information.
The unaudited pro forma condensed combined financial information has been prepared in accordance with SEC Regulation S-X Article 11 and by using the acquisition method of accounting in accordance with the business combination accounting guidance set forth in Accounting Standards Codification 805, Business Combinations. The unaudited pro forma condensed combined financial information is presented for illustrative purposes only and is not necessarily indicative of the combined operating results or financial position that would have occurred if the Merger had been consummated on the dates and in accordance with the assumptions described herein, nor is it necessarily indicative of future results of operations or financial position of the combined company.
1
On the Effective Date, Menlo issued shares of its common stock to Foamix shareholders and became the legal parent of Foamix, however, Foamix was deemed the “accounting acquirer” in the Merger. Accordingly, the below unaudited pro forma condensed combined financial information reflects Foamix acquiring Menlo, and the Merger will be accounted for as a reverse acquisition, with Foamix allocating the purchase price consideration to the tangible and intangible assets acquired and liabilities assumed from Menlo, and the excess purchase price recorded as goodwill. In accordance with reverse acquisition accounting, Foamix’s consolidated financial statements will be deemed those of the predecessor entity and will reflect the Merger with Menlo beginning on the Effective Date.
Prior to the Effective Date, Foamix conducted detailed valuation studies to determine the fair values of the Menlo assets and liabilities deemed being acquired and sought to determine whether there were any adjustments necessary to conform Menlo’s significant accounting policies to those of Foamix. Based upon Foamix’s review of Menlo’s summary of significant accounting policies, Foamix determined that there were no material adjustments in significant accounting policies required, nor were there any amounts in the historical financial statements of Menlo that were required to be reclassified in the unaudited pro forma condensed combined financial information in order to conform to Foamix’s financial statement presentation.
Under the acquisition method of accounting, the total purchase price is allocated to the assets acquired and liabilities assumed from Menlo based on their estimated fair values. The estimated fair values were determined based on valuation studies, discussions with Menlo’s management, due diligence and information presented in public filings. Historical financial information concerning Foamix and Menlo has been adjusted to give effect to matters that are (i) directly attributable to the Merger, (ii) factually supportable and (iii) with respect to the statements of operations and other comprehensive loss, expected to have a continuing impact on the operating results of the combined company.
The unaudited pro forma condensed combined financial information furthermore does not give effect to the potential impact of any anticipated synergies, operating efficiencies or cost savings that may result from the Merger, or to any integration costs.
The unaudited pro forma condensed combined financial information should be read in conjunction with the accompanying notes to the unaudited pro forma condensed combined financial information. In addition, the unaudited pro forma condensed combined financial information has been derived from and should be read in conjunction with the following, which are incorporated by reference herein:
| · | the separate historical audited financial statements of Foamix as of December 31 2019 and 2018, and for the three years ended, December 31, 2019, included in Foamix’s Annual Report on Form 10-K filed with the SEC on March 12, 2020, which are filed as Exhibit 99.1 to the Current Report on Form 8-K accompanying this unaudited pro forma condensed combined financial information; |
| · | the separate historical audited financial statements of Menlo as of December 31 2019 and 2018, and for the three years ended, December 31, 2019, included in Menlo’s Annual Report on Form 10-K filed with the SEC on March 3, 2020; |
2
Unaudited Pro Forma Condensed Combined Balance Sheet
As of December 31, 2019
(in thousands, except per share data)
| Historical | Pro Forma | Pro Forma | |||||||||||||||
| Foamix | Menlo | Adjustments | Note | Combined | |||||||||||||
| ASSETS | |||||||||||||||||
| Current assets: | |||||||||||||||||
| Cash and cash equivalents | $ | 43,759 | $ | 30,777 | $ | - | $ | 74,536 | |||||||||
| Restricted cash | 825 | - | - | 825 | |||||||||||||
| Short term bank deposits | 12,102 | - | - | 12,102 | |||||||||||||
| Investment in marketable securities | 16,246 | 46,167 | - | 62,413 | |||||||||||||
| Restricted investment in marketable securities | 434 | - | - | 434 | |||||||||||||
| Prepaid expenses, trade receivable and other current assets | 1,692 | 1,383 | - | 3,075 | |||||||||||||
| Inventory | 1,356 | - | - | 1,356 | |||||||||||||
| Total current assets | 76,414 | 78,327 | - | 154,741 | |||||||||||||
| Non-current assets | |||||||||||||||||
| Property and equipment, net | 2,885 | 98 | (98 | ) | 2,885 | ||||||||||||
| Operating lease right-of-use assets | 1,694 | 671 | (671 | ) | 4(a) | 1,694 | |||||||||||
| Prepaid expenses and other non-current assets | 166 | 73 | (73 | ) | 166 | ||||||||||||
| In-process research & development | - | - | 50,300 | 4(b) | 50,300 | ||||||||||||
| Goodwill | - | - | 4,045 | 4(c) | 4,045 | ||||||||||||
| TOTAL NON-CURRENT ASSETS | 4,745 | 842 | 53,503 | 59,090 | |||||||||||||
| Total assets | $ | 81,159 | $ | 79,169 | $ | 53,503 | $ | 213,831 | |||||||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | |||||||||||||||||
| Current liabilities: | |||||||||||||||||
| Accounts payable and accruals: | |||||||||||||||||
| Trade payables | $ | 19,352 | $ | 3,771 | $ | - | $ | 23,123 | |||||||||
| Operating lease liabilities | 1,092 | 700 | (700 | ) | 4(a) | 1,092 | |||||||||||
| Contingent stock right | - | - | 19,636 | 4(d) | 19,636 | ||||||||||||
| Employee related obligations | 5,231 | - | - | 5,231 | |||||||||||||
| Accrued expenses and other current liabilities | 3,651 | 6,190 | 14,931 | 4(e) | 24,772 | ||||||||||||
| Total current liabilities | 29,326 | 10,661 | 33,867 | 73,854 | |||||||||||||
| Long-term liabilities: | |||||||||||||||||
| Liability for employee severance benefits | 424 | - | - | 424 | |||||||||||||
| Operating lease liabilities | 653 | - | - | 653 | |||||||||||||
| Long-term debt | 32,725 | - | - | 32,725 | |||||||||||||
| Other liabilities | 456 | - | - | 456 | |||||||||||||
| Total long-term liabilities | 34,258 | - | - | 34,258 | |||||||||||||
| Total liabilities | 63,584 | 10,661 | 33,867 | 108,112 | |||||||||||||
| Commitments | |||||||||||||||||
| Shareholders’ equity: | 4(f) | ||||||||||||||||
| Stockholders’ equity | 2,659 | 3 | (2,656 | ) | 6 | ||||||||||||
| Additional paid-in capital | 325,498 | 252,820 | (147,092 | ) | 431,226 | ||||||||||||
| Accumulated deficit | (310,587 | ) | (184,339 | ) | 169,408 | (325,518 | ) | ||||||||||
| Accumulated other comprehensive income | 5 | 24 | (24 | ) | 5 | ||||||||||||
| Total shareholders’ equity | 17,575 | 68,508 | 19,636 | 105,719 | |||||||||||||
| Total liabilities and shareholders’ equity | $ | 81,159 | $ | 79,169 | $ | 53,503 | $ | 213,831 | |||||||||
See accompanying Notes to Unaudited Pro Forma Condensed Combined Financial Information.
3
Unaudited
Pro Forma Condensed Combined Statement of Operations and Other Comprehensive Loss For the Year Ended December 31, 2019
(in thousands, except per share data)
| Historical | Pro Forma | Pro Forma | |||||||||||||||
| Foamix | Menlo | Adjustments | Note | Combined | |||||||||||||
| Revenues | $ | 443 | $ | - | $ | - | $ | 443 | |||||||||
| Operating expenses: | |||||||||||||||||
| Research and development | 51,202 | 53,761 | - | 104,963 | |||||||||||||
| Selling, general and administrative | 45,114 | 22,481 | (6,914 | ) | 4(e) | 60,681 | |||||||||||
| Total operating expenses | 96,316 | 76,242 | (6,914 | ) | 165,644 | ||||||||||||
| Operating loss | 95,873 | 76,242 | (6,914 | ) | 165,201 | ||||||||||||
| Finance income and other expenses, net | (519 | ) | (2,539 | ) | - | (3,058 | ) | ||||||||||
| Loss before income tax | 95,354 | 73,703 | (6,914 | ) | 162,143 | ||||||||||||
| Income tax | (176 | ) | - | - | (176 | ) | |||||||||||
| Net loss for the period | $ | 95,178 | $ | 73,703 | $ | (6,914 | ) | $ | 161,967 | ||||||||
| Net unrealized gains from marketable securities | (47 | ) | (120 | ) | - | (167 | ) | ||||||||||
| Gains on marketable securities reclassified into net loss | 2 | - | - | 2 | |||||||||||||
| Net unrealized gains on derivative financial instruments | (3 | ) | - | - | (3 | ) | |||||||||||
| Total Other Comprehensive Income | (48 | ) | (120 | ) | - | (168 | ) | ||||||||||
| Comprehensive loss | $ | 95,130 | $ | 73,583 | $ | (6,914 | ) | $ | 161,799 | ||||||||
| Loss per share, basic and diluted | $ | 1.66 | $ | 3.09 | $ | - | $ | 2.68 | |||||||||
| Weighted-average number of shares outstanding used in computation of basic and diluted loss per share in thousands | 57,292 | 23,819 | 36,550 | 4(g) | 60,369 | ||||||||||||
See accompanying Notes to Unaudited Pro Forma Condensed Combined Financial Information.
4
NOTES TO THE UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
Note 1. Description of the Transaction
On November 10, 2019, Menlo entered into an Agreement and Plan of Merger (as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated as of December 4, 2019, the “Merger Agreement”) with Foamix, and Giants Merger Subsidiary Ltd. (“Merger Sub”), a direct and wholly-owned Israeli subsidiary of Menlo, whereby Merger Sub agreed to merge with and into Foamix, with Foamix continuing as the surviving corporation and a wholly-owned subsidiary of Menlo (the “Merger”).
On March 9, 2020 (the “Effective Date”), the Merger was completed and Foamix is now a wholly-owned subsidiary of Menlo. Foamix ceased to be an SEC reporting company as of March 19, 2020 and all future SEC filings of the combined company will be made by Menlo.
On the Effective Date, each ordinary share of Foamix was exchanged for 0.5924 shares of common stock of Menlo (the “Exchange Ratio”). In addition, on the Effective Date, Foamix shareholders received one contingent stock right (a “CSR”) for each Foamix ordinary share held by them. The CSRs were issued pursuant to the Contingent Stock Rights Agreement (the “CSR Agreement”), dated as of March 9, 2020, by and between Menlo and American Stock Transfer & Trust Company, LLC, and represented the non-transferable contractual right to receive shares of common stock of Menlo depending on the results of Menlo’s phase 3 clinical trials evaluating the safety and efficacy of once daily oral serlopitant for the treatment of prurigo nodularis (the “Phase III PN Trials”).
As previously disclosed by Menlo in its Current Report on Form 8-K filed with the SEC on April 6, 2020, each of Menlo’s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. Accordingly, pursuant to the terms of the CSR Agreement, each CSR was converted into 1.2082 shares of Menlo common stock, resulting in an effective Exchange Ratio in the Merger of 1.8006 shares of Menlo common stock for each Foamix ordinary share. Following the delivery of the shares of Menlo common stock underlying the CSRs, pre-Merger Foamix shareholders and pre-Merger Menlo stockholders own approximately 82% and 18% of post-Merger Menlo, respectively. The following unaudited pro forma condensed combined financial information does not give effect to the reported Phase III Trial results and CSR conversion.
Each of the percentages above is calculated on a fully-diluted basis using the treasury stock method and gives effect to all dilutive stock options, units and warrants outstanding as of the signing of the Merger Agreement. In addition, such percentages are based on the fully-diluted number of Foamix shares and Menlo shares on November 4, 2019 and assumes no subsequent issuances since such date.
Note 2. Basis of Pro Forma Presentation
The unaudited pro forma condensed combined financial information has been prepared in accordance with SEC Regulation S-X Article 11 and by using the acquisition method of accounting in accordance with the business combination accounting guidance set forth in Accounting Standards Codification 805, Business Combinations (“ASC 805”). The unaudited pro forma condensed combined statements of operations and other comprehensive loss for the year ended December 31, 2019, gives effect to the Merger as if it had been consummated on January 1, 2019. The unaudited pro forma condensed combined balance sheet as of December 31, 2019 gives effect to the Merger as if it had been consummated on December 31, 2019.
5
The unaudited pro forma condensed combined financial information has been derived from the historical financial statements of Foamix and Menlo that are incorporated by reference into this filing. Based upon Foamix’s review of Menlo’s summary of significant accounting policies, Foamix determined that there were no material adjustments in significant accounting policies required, nor were there any amounts in the historical financial statements of Menlo that were required to be reclassified in the unaudited pro forma condensed combined financial information in order to conform to Foamix’s financial statement presentation. ..
The unaudited pro forma condensed combined financial information has been prepared using the acquisition method of accounting in accordance with the business combination accounting guidance as provided in ASC 805, with Foamix treated as the accounting acquirer. Since Menlo is the legal acquirer, the Merger will be accounted for as a reverse acquisition. Under ASC 805, Foamix’s total estimated purchase price is calculated as described in Note 3, and the assets acquired and liabilities assumed of Menlo are measured and recorded at their estimated fair values. For the purpose of measuring the estimated fair value of the assets acquired and liabilities assumed, Foamix estimated the fair values as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the Effective Date. The fair value measurements utilize estimates based on key assumptions of the Merger, including historical and current market data.
The historical financial information has been adjusted to give effect to matters that are (i) directly attributable to the Merger, (ii) factually supportable and (iii) with respect to the statements of operations and other comprehensive loss, expected to have a continuing impact on the operating results of the combined company. Transaction costs included in the historical financial information have been excluded from the unaudited pro forma condensed combined statements of operations and other comprehensive loss as they reflect charges directly related to the Merger which do not have an ongoing impact. However, the anticipated transaction costs, which were not included in the historical financial information, are reflected in the unaudited pro forma condensed combined balance sheet as an increase to accounts payable and other current liabilities and a decrease to retained earnings (which is an increase to accumulated deficit, in the case of the combined company). In addition, the unaudited pro forma condensed combined statement of operations and other comprehensive loss does not include anticipated one-time costs directly attributable to the transaction, employee retention costs or professional fees incurred or to be incurred by Foamix or Menlo pursuant to provisions contained in the Merger Agreement.
The combined company expects to incur significant costs associated with integrating the operations of Foamix and Menlo after the Merger is completed. The unaudited pro forma condensed combined financial information do not reflect the costs of any integration activities or benefits that may result from realization of future cost savings from operating efficiencies or revenue synergies expected to result from the Merger.
Note 3. Estimate of Consideration Expected to be Transferred
The following is the Merger Consideration (as defined in the Merger Agreement) to be transferred to effect the Merger:
| (in thousands, except share data) | Total | |||
| Deemed (for accounting purposes only) issuance of Foamix shares to Menlo stockholders | $ | 123,757 | ||
| Deemed (for accounting purposes only) conversion of Menlo equity awards | 7,322 | |||
| Total consideration* | $ | 131,079 | ||
* This amount reflects total consideration prior to reduction in respect of the CSRs that were issued to Foamix shareholders and that reduced the Menlo stockholders’ relative ownership in the combined company. If the effect of the CSRs is included, the total consideration deemed paid by Foamix, as the accounting acquirer, to Menlo stockholders and equity award holders in the Merger would be reduced to approximately $111.4 million, as shown in the purchase price allocation table further below in this Note 3.
6
Based on Foamix’s closing share price of $2.99 as of March 9, 2020, the Merger Consideration under reverse acquisition accounting would be approximately $131.1 million, consisting of $123.8 million for the deemed (for accounting purposes only) issuance of 41.4 million Foamix shares assuming that no upwards adjustment was made to the Exchange Ratio relating to the CSR, and $7.3 million for the fair value of Menlo equity awards deemed (for accounting purposes only) to be converted into Foamix equity awards. The converted stock options represent the fair value of such options attributable to service prior to the Merger date using the Foamix closing share price of $2.99 as of March 9, 2020 as an input to the Black Scholes valuation model to determine the fair value of the options.
The allocation of the purchase price to the fair values of assets acquired and liabilities assumed includes unaudited pro forma adjustments to reflect the fair value of Menlo’s assets and liabilities. The allocation of the purchase price is as follows:
| (in thousands) | ||||
| Cash and cash equivalents | $ | 38,641 | ||
| Investment in marketable securities | 22,703 | |||
| Prepaid expenses and other current assets | 1,581 | |||
| In-process R&D | 50,300 | |||
| Goodwill | 4,045 | |||
| Total assets | 117,270 | |||
| Current liabilities | (5,827 | ) | ||
| Total liabilities | (5,827 | ) | ||
| Estimated purchase price * | $ | 111,443 | ||
* Reflects reduction in the purchase price deemed paid to Menlo stockholders in the Merger on the assumption that the CSRs, in an aggregate value of $19.6 million, convert into additional shares of the combined company for the Foamix shareholders, thereby resulting in a lower percentage of the combined company’s outstanding shares being owned by Menlo stockholders following the Merger, see Note 4(d). As previously disclosed by Menlo in its Current Report on Form 8-K filed with the SEC on April 6, 2020, each of Menlo’s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. Accordingly, pursuant to the terms of the CSR Agreement, each CSR was converted into 1.2082 shares of Menlo common stock, resulting in an effective Exchange Ratio in the Merger of 1.8006 shares of Menlo common stock for each Foamix ordinary share. Following the delivery of the shares of Menlo common stock underlying the CSRs, pre-Merger Foamix shareholders and pre-Merger Menlo stockholders own approximately 82% and 18% of post-Merger Menlo, respectively, each calculated on a fully diluted basis. The following unaudited pro forma condensed combined financial information does not give effect to the reported Phase III Trial results and CSR conversion as it occurred after the Effective Date.
7
Note 4. Adjustments to Unaudited Pro Forma Condensed Combined Financial Statements
The unaudited adjustments included in the unaudited pro forma condensed combined financial information are as follows:
Adjustments to Unaudited Pro Forma Condensed Combined Statements of Operations and Other Comprehensive Loss and Condensed Combined Balance Sheets
(a) Operating lease right-of-use asset and liabilities. Reflects the removal of the operating lease right-of-use asset and liability related to Menlo’s Redwood City, CA facility from the accompanying unaudited pro forma condensed combined balance sheet. As the lease term is less than 12 months, the combined company expects to keep the lease off the balance sheet and recognize the lease payments in its statements of operations and comprehensive loss on a straight-line basis over the remaining lease term.
(b) Other intangible assets. Represents the unaudited pro forma adjustment to reflect the fair value of Menlo’s intangible assets of approximately $50.3 million.
Identified intangibles assets acquired consist of the following (in millions):
| Intangible asset | Estimated Fair Value | |||
| Acquired indefinite life intangible assets(1) | $ | 50,300 | ||
| Estimated fair value of identified intangible assets | $ | 50,300 | ||
(1) Represents acquired IPR&D assets which are initially recognized at fair value and are classified as indefinite-lived assets until the successful completion or abandonment of the associated research and development efforts. Accordingly, during the research and development period after the Effective Date of the combination, these assets will not be amortized into earnings; instead these assets will be subject to periodic impairment testing. Upon successful completion of the development process for an acquired IPR&D project, determination as to the useful life of the asset will be made; at that point in time, the asset would then be considered a finite-lived intangible asset and would be amortized into earnings. Following the reported results of the Phase III PN Trials as described in Note 1, Menlo expects to record an impairment charge related to the IPR&D assets in its consolidated statement of operations and comprehensive loss for the three-months and six-months ending June 30, 2020, see Note 5.
(c) Goodwill. Reflects the excess of the purchase price paid over the fair value of Menlo’s net tangible and identifiable intangible assets and liabilities, assumed. Goodwill will not be amortized but will be tested for impairment annually or when events or circumstances change that could potentially reduce the fair value. The estimated purchase price of the transaction and the excess purchase price over the fair value of the identifiable net assets acquired, are calculated as follows (in thousands):
| Purchase price | $ | 111,443 | ||
| Less: fair value of net assets acquired, including other identifiable intangibles | (107,398 | ) | ||
| Pro forma goodwill adjustment | $ | 4,045 |
Following the reported results of the Phase III PN Trials as described in Note 1, Menlo expects to record an impairment charge related to the Goodwill assets in its consolidated statement of operations and comprehensive loss for the three-months and six-months ending June 30, 2020, see Note 5.
(d) Contingent Stock Right (“CSR”). The CSR in an amount of $19.6 million is recognized as a liability in the unaudited pro forma condensed combined balance sheet. The liability is measured at fair value as of the acquisition date in accordance with ASC 805-31-25-5 and subsequently at each reporting date thereafter. The issuance of the CSR was dependent on (i) the Merger being completed prior to May 31, 2020 and (ii) the Efficacy Determination not being delivered to Menlo and Foamix on or before the date the Merger is completed. The fair value of the CSR as recorded in the unaudited pro forma condensed combined balance sheet takes into consideration the probabilities of the following scenarios (a) Serlopitant Significance was achieved in both Phase III PN Trials (b) Serlopitant Significance was achieved in only one Phase III PN Trial and (c) Serlopitant Significance was not achieved or has not been determined on or before May 31, 2020.
8
As previously disclosed by Menlo in its Current Report on Form 8-K filed with the SEC on April 6, 2020, each of Menlo’s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. Accordingly, pursuant to the terms of the CSR Agreement, each CSR was converted into 1.2082 shares of Menlo common stock, resulting in an effective Exchange Ratio in the Merger of 1.8006 shares of Menlo common stock for each Foamix ordinary share. Following the delivery of the shares of Menlo common stock underlying the CSRs, pre-Merger Foamix shareholders and pre-Merger Menlo stockholders own approximately 82% and 18% of post-Merger Menlo, respectively, each calculated on a fully diluted basis. The unaudited pro forma condensed combined financial information does not give effect to the reported Phase III Trial results and CSR conversion.
(e) Acrrued expenses and other current liabilities. Total transaction costs and other non-reccuring costs related to the Merger are estimated to be $21.8 million. Transaction costs of $6.9 million were included the historical financial information and have been recorded as an adjustment in selling, general and administrative expenses within the unaudited pro forma condensed combined statements of operations and other comprehensive loss for the year ended December 31, 2019. The adjustment amount of $14.9 million recorded as an increase to accounts payable and other current liabilities in the accompanying unaudited pro forma condensed combined balance sheet represents the remaining estimated transaction costs expected to be incurred by the combined company.
Total Menlo transaction costs and other non-reccuring costs related to the Merger are estimated to be $15.0 million, including $8.1 million of estimated severance benefits for employees expected to be terminated after the Effective Date. Approximately $3.1 million of Menlo transaction costs were included in the historical financial information and have been recorded as an adjustment in selling, general and administrative expenses within the unaudited pro forma condensed combined statements of operations and other comprehensive loss for the year ended December 31, 2019. Approximately $11.9 million of estimated Menlo transaction costs which were not included in the historical financial information, have been recorded as an increase to accounts payable and other current liabilities in the accompanying unaudited pro forma condensed combined balance sheet represents the remaining estimated transaction costs expected to be incurred.
Total Foamix transaction costs and other non-reccuring costs related to the Merger are estimated to be $6.8 million, of which approximately $3.8 million were included in the historical financial information and have been recorded as an adjustment in selling, general and administrative expenses within the unaudited pro forma condensed combined statement of operations and other comprehensive loss for the year ended December 31, 2019. Approximately, $3.0 million of estimated Foamix transaction costs which were not included in the historical financial information, have been recorded as an increase to accounts payable and other current liabilities in the accompanying unaudited pro forma condensed combined balance sheet and represents the remaining estimated transaction costs expected to be incurred.
(f) Stockholders’ equity. Under reverse acquisition accounting, the amount of common stock reflects the equity structure of the legal acquirer (the par value and the number of shares of common stock issued by Menlo). The unaudited pro forma condensed combined balance sheet reflects the elimination of Foamix’s historical ordinary shares and the recognition of approximately 36.6 million shares, par value $0.0001 per share, of Menlo common stock that was issued and outstanding upon consummation of the Merger (equal to $3.7 thousand of common stock, and not including the CSR conversion, see Note 5). The amount of additional paid-in capital represents that of Foamix, as adjusted to reflect the purchase price related to Foamix shares deemed (for accounting purposes) issued in the Merger, less the par value of the shares of Menlo common stock outstanding after the combination and includes $7.3 million to reflect the portion of the purchase price related to the total estimated fair value of Menlo equity awards deemed (for accounting purposes only) to be converted into Foamix equity awards (Menlo stock options and Menlo RSUs outstanding as of March 9, 2020). The converted stock options represent the fair value of such options attributable to service prior to the Merger date using the Foamix closing share price of $2.99 as of March 9, 2020 as an input to the Black Scholes valuation model to determine the fair value of the options.
9
Accumulated deficit of Foamix as the accounting acquirer was increased by $14.9 million for estimated transaction costs as further described in Note 4(e). These estimated transaction costs have been excluded from the unaudited pro forma condensed combined statement of operations and other comprehensive loss as they reflect charges directly related to the Merger that do not have an ongoing impact.
(g) Shares outstanding. The unaudited pro forma weighted average number of basic and diluted shares outstanding is calculated for the period presented by adding Menlo’s weighted number of basic shares of common stock outstanding for that period and the number of Menlo shares of common stock that would have been issued to Foamix shareholders as a result of the Merger and assuming that no upwards adjustment is made to the Exchange Ratio relating to the CSR.
Note 5. Subsequent Event
As previously disclosed by Menlo in its Current Report on Form 8-K filed with the SEC on April 6, 2020, each of Menlo’s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. As a result, Menlo does not intend to pursue the development. Accordingly, Menlo expects to record a full impairment charge related to the IPR&D and Goodwill assets further described in Note 4(b) and Note 4(c), respectively, in its consolidated statement of operations and comprehensive loss for the three-months and six-months ending June 30, 2020. In addition, pursuant to the terms of the CSR Agreement, each CSR was converted into 1.2082 shares of Menlo common stock, resulting in an effective Exchange Ratio in the Merger of 1.8006 shares of Menlo common stock for each Foamix ordinary share. On April 6, 2020, the CSR conversion resulted in the issuance and delivery of 74,544,413 shares of Menlo common stock underlying the CSRs. As a result, the loss per share was decreased by $1.48 per share, from $2.68 per share to $1.2 per share, on a pro forma basis for the year ended December 31, 2019. The conversion of the CSR also affected the Exchange Ratio applicable to the pre-Merger Foamix equity awards and warrants outstanding as of March 9, 2020 in a manner consistent with the foregoing.
10